65. 原発性免疫不全症候群 Disease details / Clinical trials / Drug dev / DR info

0.9% sodium chloride
   AB2 Bio Ltd.
      2017   Phase 3   NCT03113760   Canada;Germany;United States
16,5% cutaquig
   Ottawa Hospital Research Institute
      2018   Phase 4   NCT03677557   Canada
2(S)-(acetylamino)-4-methylpentanoic acid
   IntraBio Ltd
      2020   Phase 2   EUCTR2018-004407-39-DE   Germany;Spain;United Kingdom;United States
A10bk03
   Cliniques universitaires Saint-Luc
      2019   Phase 4   EUCTR2018-004191-35-BE   Belgium
Abatacept
   Children's Hospital Medical Center, Cincinnati
      2021   Phase 2   NCT04925375   United States
   Emory University
      2014   Phase 1   NCT01917708   United States
   ISTITUTO PER L`INFANZIA BURLO GAROFOLO
      2008   -   EUCTR2008-003368-21-IT   Italy
   Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
      2016   Phase 2   EUCTR2015-002491-24-DE   Germany
Acetamide
   Academisch Medisch Centrum
      2021   Phase 2   EUCTR2021-000720-36-NL   Netherlands
Adagen
   Leadiant Biosciences, Inc.
      2014   Phase 3   NCT01420627   United States
Adenosine
   University of California, Los Angeles
      2019   -   NCT04049084   United Kingdom;United States
Administration OF drug (interferon-gamma 1-B) subcutaneously
   University of Colorado, Denver
      2016   Phase 1   NCT02609932   United States
Adverse reactions OF gammagard subcutaneously AT week 12
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Adverse reactions OF gammagard subcutaneously AT week 24
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Adverse reactions OF gammagard subcutaneously AT week 36
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Adverse reactions OF gammagard subdermally AT week 12
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Adverse reactions OF gammagard subdermally AT week 24
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Adverse reactions OF gammagard subdermally AT week 36
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
ADX-324
   ADARx Pharmaceuticals, Inc.
      2025   Phase 3   NCT06960213   -
      2022   Phase 1/Phase 2   NCT05691361   Australia
Aldesleukin
   Universitätsklinikum Freiburg
      2016   Phase 2   EUCTR2015-003369-27-DE   Germany
Alefacept
   Emory University
      2010   -   NCT01319851   United States
Alemtuzumab
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 1;Phase 2   EUCTR2014-005585-30-FR   France
   Baylor College of Medicine
      2004   Phase 2   NCT00578643   United States
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States
   Karolinska Universitetssjukhuset
      2018   Phase 2   EUCTR2018-001489-41-SE   Sweden;United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2015   -   NCT02162420   United States
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT05463133   United States
      2019   Early Phase 1   NCT03910452   United States
      2015   Phase 1/Phase 2   NCT02629120   United States
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States
Alemtuzumab 0.2 MG
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States
Alemtuzumab 0.3 MG
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States
Allo BMT
   National Cancer Institute (NCI)
      2015   Phase 2   NCT02579967   United States
Allogeneic bone marrow transplantation
   Fairview University Medical Center
      2000   -   NCT00006054   United States
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
      1997   Phase 1   NCT00008450   United States
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States
      2005   Phase 1   NCT00295971   United States
      2000   Phase 1/Phase 2   NCT00305708   United States
Allogeneic hematopoietic stem cell transplantation
   Fairview University Medical Center
      2000   -   NCT00006056   United States
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States
      2005   Phase 1   NCT00295971   United States
Allogeneic HSC
   National Cancer Institute (NCI)
      2018   Phase 2   NCT03663933   United States
Allogeneic hsct
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States
Allogeneic peripheral blood stem cell
   National Institute of Allergy and Infectious Diseases (NIAID)
      2019   Early Phase 1   NCT03910452   United States
ANTI-CD45
   Baylor College of Medicine
      2007   Phase 1/Phase 2   NCT00579137   United States
ANTI-thymocyte globulin
   Fairview University Medical Center
      2000   -   NCT00006056   United States
      2000   -   NCT00006054   United States
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States
      2000   Phase 2/Phase 3   NCT00176878   United States
   University of California, San Francisco
      2005   Phase 1   NCT00295971   United States
      2000   Phase 1/Phase 2   NCT00305708   United States
Antithymocyte globulin
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States
AP1903
   Baylor College of Medicine
      2011   Phase 1   NCT01494103   United States
ARA-C
   Baylor College of Medicine
      2000   Phase 2   NCT00368355   United States
Argininhydrochlorid
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany
Autologous CD34 positive cells transduced with A lentiviral vector containing human WAS gene
   Genethon
      2011   Phase 1/Phase 2   NCT01347346   France
      2011   Phase 1/Phase 2   NCT01347242   United Kingdom
Autologous CD34+ cells transduced EX-vivo with THE pcclchimgp91/vsvg lentiviral vector
   GENETHON
      2013   Phase 1;Phase 2   EUCTR2012-000242-35-DE   France;Germany;Switzerland;United Kingdom
   Genethon
      2015   Phase 1;Phase 2   EUCTR2014-002222-12-FR   France
      2013   Phase 1;Phase 2   EUCTR2012-000242-35-GB   France;Germany;Switzerland;United Kingdom
Autologous CD34+ cells transduced with THE G1xcgd lentiviral vector
   Genethon
      2015   Phase 1;Phase 2   EUCTR2014-002222-12-FR   France
Autologous CD34+ cells transduced with THE lentiviral vector containing THE human wiskott aldrich SY
   GENETHON
      -   Phase 1;Phase 2   EUCTR2009-011152-22-FR   France
Autologous CD34+ cells transduced with wasp lentiviral vector
   Genethon
      2014   Phase 1/Phase 2   NCT02333760   France;United Kingdom
Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes FOR THE human wiskott aldrich syndrome (WAS) cdna sequence
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
Autologous CD34+ hscs transduced EX vivo with EFS lentiviral vector encoding FOR THE human ADA gene
   Great Ormond Street Hospital for Children NHS Trust
      2017   Phase 2   EUCTR2017-001275-23-GB   United Kingdom
Autologous CD34+cells transduced with THE W1.6_hwasp_wpre (vsvg) lentiviral vector
   Genethon
      2014   Phase 2   EUCTR2014-000274-20-GB   United Kingdom
      2014   Phase 2   EUCTR2014-000274-20-FR   France;United Kingdom
      2010   Phase 1;Phase 2   EUCTR2007-004308-11-GB   United Kingdom
Avoralstat
   BIOCRYST PHARMACEUTICALS INC.
      2015   Phase 3   EUCTR2015-003242-22-IT   Belgium;Canada;France;Germany;Hungary;Italy;United Kingdom;United States
   BioCryst Pharmaceuticals
      2015   Phase 3   NCT02670720   Belgium;France
   BioCryst Pharmaceuticals Inc
      2015   -   EUCTR2015-003242-22-HU   Canada;France;Germany;Hungary;United States
      2015   Phase 3   EUCTR2015-003242-22-GB   Belgium;Canada;France;Germany;Hungary;United Kingdom;United States
      2015   Phase 3   EUCTR2015-003242-22-FR   Belgium;Canada;France;Germany;Hungary;United States
      2015   Phase 3   EUCTR2015-003242-22-DE   Belgium;Canada;France;Germany;Hungary;Italy;United Kingdom;United States
      2015   Phase 3   EUCTR2015-003242-22-BE   Belgium;Canada;France;Germany;Hungary;United States
AVTX-803
   AUG Therapeutics
      2023   Phase 3   NCT05754450   United States
      2022   Phase 3   NCT05462587   United States
Azathioprine
   Medical College of Wisconsin
      2016   Phase 2   NCT02789397   -
Baclofen
   Johns Hopkins University
      2007   Early Phase 1   NCT00640003   United States
Bacteriophage
   National Institute of Allergy and Infectious Diseases (NIAID)
      1999   Phase 2   NCT00001145   United States
BASE-edited hematopoietic stem and progenitor cells
   National Institute of Allergy and Infectious Diseases (NIAID)
      2025   Phase 1/Phase 2   NCT06851767   United States
      2024   Phase 1/Phase 2   NCT06325709   United States
BC7353
   BioCryst Pharmaceuticals Inc
      2016   -   EUCTR2015-003923-74-HU   Canada;Germany;Hungary;United Kingdom
      2015   Phase 2   EUCTR2015-003923-74-GB   Canada;Germany;Hungary;United Kingdom
BCX4161
   BIOCRYST PHARMACEUTICALS INC.
      2015   Phase 3   EUCTR2015-003242-22-IT   Belgium;Canada;France;Germany;Hungary;Italy;United Kingdom;United States
      2015   -   EUCTR2014-002655-26-IT   France;Germany;Hungary;Italy;Switzerland;United Kingdom;United States
   BioCryst Pharmaceuticals
      2014   Phase 2/Phase 3   NCT02303626   Belgium;Canada;France;Germany;Hungary;Italy;United Kingdom;United States
      2014   Phase 1   NCT02218294   United Kingdom
      2014   Phase 1   NCT02125162   United Kingdom
      2013   Phase 2   NCT01984788   Germany;United Kingdom
   BioCryst Pharmaceuticals Inc
      2015   -   EUCTR2015-003242-22-HU   Canada;France;Germany;Hungary;United States
      2015   Phase 3   EUCTR2015-003242-22-GB   Belgium;Canada;France;Germany;Hungary;United Kingdom;United States
      2015   Phase 3   EUCTR2015-003242-22-FR   Belgium;Canada;France;Germany;Hungary;United States
      2015   Phase 3   EUCTR2015-003242-22-DE   Belgium;Canada;France;Germany;Hungary;Italy;United Kingdom;United States
      2015   Phase 3   EUCTR2015-003242-22-BE   Belgium;Canada;France;Germany;Hungary;United States
      2015   -   EUCTR2014-002655-26-HU   France;Germany;Hungary;Italy;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2014-002655-26-GB   Belgium;France;Germany;Hungary;Italy;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2014-002655-26-FR   Belgium;France;Germany;Hungary;Italy;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2014-002655-26-DE   Belgium;France;Germany;Hungary;Italy;Switzerland;United Kingdom;United States
      2015   Phase 3   EUCTR2014-002655-26-BE   Belgium;Canada;France;Germany;Hungary;Italy;United Kingdom;United States
   BioCryst Pharmaceuticals Inc.
      2014   Phase 2   EUCTR2013-002319-82-GB   Germany;United Kingdom
      2013   -   EUCTR2013-002319-82-DE   Germany;United Kingdom
BCX7353
   BIOCRYST PHARMACEUTICALS INC.
      2023   Phase 3   EUCTR2021-005932-50-IT   Austria;Canada;France;Germany;Hungary;Israel;Italy;North Macedonia;Poland;Romania;Spain;United Kingdom
      2018   Phase 3   EUCTR2017-003966-29-IT   Austria;Belgium;Bulgaria;Czech Republic;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;Spain;United Kingdom
      2018   Phase 2   EUCTR2017-003281-27-IT   Argentina;Australia;Austria;Belgium;Colombia;Denmark;European Union;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Netherlands;New Zealand;North Macedonia;Poland;Serbia;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
   BioCryst Pharmaceuticals
      2018   Phase 2/Phase 3   NCT03472040   Australia;Austria;Denmark;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Macedonia, The Former Yugoslav Republic of;New Zealand;North Macedonia;Poland;Serbia;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States
      2017   Phase 2   NCT03240133   Austria;Denmark;France;Germany;Hungary;Israel;Italy;Macedonia, The Former Yugoslav Republic of;North Macedonia;Poland;Romania;Switzerland;United Kingdom
      2017   Phase 1   NCT03202784   United Kingdom
      2016   Phase 2   NCT02870972   Australia;Austria;Canada;Denmark;Germany;Hungary;Italy;Macedonia, The Former Yugoslav Republic of;Spain;Switzerland;United Kingdom
      2015   Phase 1   NCT02448264   United Kingdom
   BioCryst Pharmaceuticals Inc
      2021   Phase 3   EUCTR2020-004230-37-SK   Czech Republic;European Union;France;Korea, Republic of;North Macedonia;Poland;Slovakia;South Africa
      2021   Phase 3   EUCTR2020-004230-37-PL   Czech Republic;European Union;France;Korea, Republic of;North Macedonia;Poland;Slovakia;South Africa
      2021   Phase 3   EUCTR2020-004230-37-CZ   Czech Republic;Czechia;European Union;France;Korea, Republic of;North Macedonia;Poland;Slovakia;South Africa
      2018   Phase 2   EUCTR2017-003281-27-SK   Australia;Austria;Belgium;Denmark;European Union;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;Spain;Switzerland;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003281-27-PL   Australia;Austria;Belgium;Denmark;European Union;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003281-27-NL   Australia;Austria;Belgium;Denmark;European Union;Germany;Hong Kong;Hungary;Israel;Korea, Republic of;Netherlands;New Zealand;North Macedonia;Poland;Serbia;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003281-27-HU   Australia;Austria;Belgium;Denmark;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Slovakia;Spain;Switzerland;United Kingdom
      2018   Phase 2   EUCTR2017-003281-27-ES   Australia;Austria;Belgium;Denmark;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;Slovakia;Spain;Switzerland;United Kingdom
      2018   Phase 2   EUCTR2017-003281-27-DK   Australia;Austria;Belgium;Denmark;European Union;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003281-27-DE   Australia;Austria;Belgium;Denmark;European Union;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003281-27-BE   Australia;Austria;Belgium;Denmark;European Union;Germany;Hong Kong;Hungary;Israel;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;South Africa;Spain;Switzerland;United Kingdom
      2018   Phase 2   EUCTR2017-003281-27-AT   Austria;Belgium;Denmark;European Union;Germany;Hong Kong;Hungary;Israel;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States
      2017   Phase 2   EUCTR2017-003281-27-GB   Austria;Belgium;Denmark;European Union;Germany;Hong Kong;Hungary;Israel;Korea, Republic of;Macedonia, the former Yugoslav Republic of;Netherlands;New Zealand;Poland;Serbia;Slovakia;South Africa;Spain;Switzerland;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001272-29-GR   Australia;Austria;Canada;Denmark;European Union;Germany;Greece;Hungary;Macedonia, the former Yugoslav Republic of;Spain;Switzerland;United Kingdom
      2016   Phase 2   EUCTR2016-001272-29-HU   Austria;Canada;Denmark;European Union;Germany;Greece;Hungary;Spain;Switzerland;United Kingdom
      2016   Phase 2   EUCTR2016-001272-29-GB   Australia;Austria;Canada;Denmark;European Union;Germany;Greece;Hungary;Macedonia, the former Yugoslav Republic of;Spain;Switzerland;United Kingdom
      2016   Phase 2   EUCTR2016-001272-29-ES   Austria;Canada;Denmark;European Union;Germany;Greece;Hungary;Spain;Switzerland;United Kingdom
      2016   Phase 2   EUCTR2016-001272-29-DK   Australia;Austria;Canada;Denmark;European Union;Germany;Greece;Hungary;Macedonia, the former Yugoslav Republic of;Spain;Switzerland;United Kingdom
      2016   Phase 2   EUCTR2016-001272-29-DE   Australia;Austria;Canada;Denmark;European Union;Germany;Greece;Hungary;Macedonia, the former Yugoslav Republic of;Spain;Switzerland;United Kingdom
      2016   Phase 2   EUCTR2016-001272-29-AT   Australia;Austria;Canada;Denmark;European Union;Germany;Greece;Hungary;Macedonia, the former Yugoslav Republic of;Spain;Switzerland;United Kingdom
      2016   -   EUCTR2015-003923-74-HU   Canada;Germany;Hungary;United Kingdom
      2015   Phase 2   EUCTR2015-003923-74-GB   Canada;Germany;Hungary;United Kingdom
      -   Phase 3   EUCTR2020-004230-37-FR   Czech Republic;European Union;France;Korea, Republic of;North Macedonia;Poland;Slovakia;South Africa
   BioCryst Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2017-003966-29-RO   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Ireland;Italy;Netherlands;North Macedonia;Romania;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003966-29-NL   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Ireland;Macedonia, the former Yugoslav Republic of;Netherlands;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003966-29-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003966-29-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Romania;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003966-29-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Romania;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003966-29-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003966-29-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003966-29-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-001424-55-PL   Austria;Denmark;European Union;Germany;Hungary;Israel;Macedonia, the former Yugoslav Republic of;Poland;Switzerland;United Kingdom
      2017   Phase 2   EUCTR2016-001424-55-HU   Australia;Austria;Canada;Denmark;European Union;Germany;Hungary;Israel;Macedonia, the former Yugoslav Republic of;Poland;Switzerland;United Kingdom
      2017   Phase 2   EUCTR2016-001424-55-GB   Austria;Denmark;European Union;Germany;Hungary;Israel;Macedonia, the former Yugoslav Republic of;Poland;Switzerland;United Kingdom
      2017   Phase 2   EUCTR2016-001424-55-DK   Austria;Denmark;European Union;Germany;Hungary;Israel;Macedonia, the former Yugoslav Republic of;Poland;Switzerland;United Kingdom
      2017   Phase 2   EUCTR2016-001424-55-DE   Austria;Denmark;European Union;Germany;Hungary;Israel;Macedonia, the former Yugoslav Republic of;Poland;Switzerland;United Kingdom
      2017   Phase 2   EUCTR2016-001424-55-AT   Austria;Denmark;European Union;Germany;Hungary;Israel;Macedonia, the former Yugoslav Republic of;Poland;Switzerland;United Kingdom
      -   Phase 3   EUCTR2017-003966-29-IE   Austria;Bulgaria;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Ireland;Macedonia, the former Yugoslav Republic of;Netherlands;United States
      -   Phase 3   EUCTR2017-003966-29-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;European Union;France;Germany;Hungary;Ireland;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2017-003966-29-DK   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Ireland;Macedonia, the former Yugoslav Republic of;Netherlands;United States
      -   Phase 3   EUCTR2017-003966-29-BG   Austria;Bulgaria;Canada;Czech Republic;Denmark;European Union;Germany;Hungary;Ireland;Macedonia, the former Yugoslav Republic of;Netherlands;United States
   BioCryst Pharmaceuticals, Inc.
      2023   Phase 3   EUCTR2021-005932-50-PL   Austria;Canada;France;Germany;Israel;Italy;Poland;Romania;Spain;United Kingdom
      2022   Phase 3   EUCTR2021-005932-50-FR   Austria;Canada;France;Germany;Hungary;Israel;Italy;North Macedonia;Poland;Romania;Spain;United Kingdom
      2022   Phase 3   EUCTR2021-005932-50-DE   Austria;Canada;France;Germany;Israel;Italy;Poland;Romania;Spain;United Kingdom
      2022   Phase 3   EUCTR2021-005932-50-AT   Austria;Canada;France;Germany;Israel;Italy;Poland;Romania;Spain;United Kingdom
BCX7353 + digoxin
   BioCryst Pharmaceuticals
      2017   Phase 1   NCT03136237   United Kingdom
BCX7353 and probes
   BioCryst Pharmaceuticals
      2016   Phase 1   NCT02819102   United Kingdom
BCX7353 capsules
   BioCryst Pharmaceuticals
      2019   Phase 3   NCT03873116   Japan
      2018   Phase 3   NCT03485911   Austria;Canada;Czechia;France;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;North Macedonia;Romania;Spain;United Kingdom;United States
   BioCryst Pharmaceuticals, Inc.
      2018   Phase 3   JPRN-UMIN000034869   Japan
Berinert
   CSL Behring
      2013   Phase 1   NCT01760343   Germany
      2010   -   NCT01108848   Denmark;Germany;Switzerland;United States
   CSL Behring GmbH
      2013   -   EUCTR2010-024242-30-BG   Bulgaria;Hungary;Poland
      2011   -   EUCTR2010-024242-30-PL   Bulgaria;Hungary;Poland
      2011   Phase 4   EUCTR2010-024242-30-HU   Bulgaria;Hungary;Poland
   ZLB Behring GmbH
      -   -   EUCTR2005-003139-38-Outside-EU/EEA   Canada;United States
Berinert P
   CSL Behring GmbH
      2007   -   EUCTR2004-001186-17-BG   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2004-001186-17-SE   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2004-001186-17-CZ   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
   Fachbereich Medizin der Johann Wolfgang Goethe-Universität Frankfurt/M.
      2008   -   EUCTR2008-000654-12-DE   Germany
Berinert*IV FL 500U+FL 10ML
   AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
      2013   -   EUCTR2010-019670-32-IT   Italy
Berinert, lyophilizate FOR IV application containing 500 IU C1-INH TO BE reconstituted with 10 ML water FOR injection
   CSL Behring
      2011   Phase 4   NCT01467947   Bulgaria;Hungary;Poland;Romania
Berinert® P
   ZLB Behring GmbH
      2005   Phase 3   EUCTR2004-001186-17-HU   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-001186-17-ES   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
Berinert®, 20 ??/ KG
   AO GENERIUM
      2021   Phase 2/Phase 3   NCT04898309   Russian Federation
Berotralstat
   BIOCRYST PHARMACEUTICALS INC.
      2023   Phase 3   EUCTR2021-005932-50-IT   Austria;Canada;France;Germany;Hungary;Israel;Italy;North Macedonia;Poland;Romania;Spain;United Kingdom
   BioCryst Pharmaceuticals
      2022   Phase 3   NCT05453968   Austria;Canada;France;Germany;Israel;Italy;North Macedonia;Poland;Romania;Spain;United Kingdom
      2021   Phase 3   NCT04933721   Czechia;France;Korea, Republic of;North Macedonia;Poland;Slovakia;South Africa
      2020   -   NCT04428632   -
   BioCryst Pharmaceuticals Inc
      2021   Phase 3   EUCTR2020-004230-37-SK   Czech Republic;European Union;France;Korea, Republic of;North Macedonia;Poland;Slovakia;South Africa
      2021   Phase 3   EUCTR2020-004230-37-PL   Czech Republic;European Union;France;Korea, Republic of;North Macedonia;Poland;Slovakia;South Africa
      2021   Phase 3   EUCTR2020-004230-37-CZ   Czech Republic;Czechia;European Union;France;Korea, Republic of;North Macedonia;Poland;Slovakia;South Africa
      -   Phase 3   EUCTR2020-004230-37-FR   Czech Republic;European Union;France;Korea, Republic of;North Macedonia;Poland;Slovakia;South Africa
   BioCryst Pharmaceuticals, Inc.
      2023   Phase 3   EUCTR2021-005932-50-PL   Austria;Canada;France;Germany;Israel;Italy;Poland;Romania;Spain;United Kingdom
      2022   Phase 3   EUCTR2021-005932-50-FR   Austria;Canada;France;Germany;Hungary;Israel;Italy;North Macedonia;Poland;Romania;Spain;United Kingdom
      2022   Phase 3   EUCTR2021-005932-50-DE   Austria;Canada;France;Germany;Israel;Italy;Poland;Romania;Spain;United Kingdom
      2022   Phase 3   EUCTR2021-005932-50-AT   Austria;Canada;France;Germany;Israel;Italy;Poland;Romania;Spain;United Kingdom
Betamethasone oral solution period 1 and period 2
   Acasti Pharma Inc.
      2022   Phase 1   NCT05531890   Canada
Betamethasone solution AS intramuscular injection period 1 and period 2
   Acasti Pharma Inc.
      2022   Phase 1   NCT05531890   Canada
Biological NTLA-2002
   Intellia Therapeutics
      2021   Phase 1/Phase 2   NCT05120830   Australia;France;Germany;Netherlands;New Zealand;United Kingdom
Biological sampling
   Imagine Institute
      2015   -   NCT02909244   France
Biopsy
   University Hospital Freiburg
      2007   -   NCT00499070   Austria;Belgium;Czech Republic;Denmark;Germany;Ireland;Italy;Netherlands;Poland;Spain;Switzerland
Biopsy procedure
   National Cancer Institute (NCI)
      2023   Phase 1/Phase 2   NCT05691491   United States
Biospecimen collection
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
   National Cancer Institute (NCI)
      2023   Phase 1/Phase 2   NCT05691491   United States
Bivigam
   ADMA Biologics, Inc.
      2016   -   NCT03037359   United States
Blood draw
   Enzyvant Therapeutics GmBH
      2005   Phase 1/Phase 2   NCT00579527   United States
   Sumitomo Pharma Switzerland GmbH
      2010   -   NCT01220531   United States
Blood drawing IN healthy controls
   Weill Medical College of Cornell University
      2009   Phase 2   NCT00909363   United States
Blood drawing IN patients with WAS
   Weill Medical College of Cornell University
      2009   Phase 2   NCT00909363   United States
Blood sample
   Koneti Rao
      2008   Phase 1/Phase 2   NCT00605657   United States
BMS-188667
   Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
      2016   Phase 2   EUCTR2015-002491-24-DE   Germany
Bone marrow aspiration
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Bone marrow biopsy
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Boya ivig
   Azidus Brasil
      2024   Phase 3   NCT06150833   -
BPX-501 T cells
   Bellicum Pharmaceuticals
      2014   Phase 1/Phase 2   NCT02065869   Germany;Italy;Spain;United Kingdom;United States
BT090
   Biotest AG
      2010   -   EUCTR2010-019249-25-HU   Germany;Hungary
      2010   -   EUCTR2010-019249-25-DE   Germany;Hungary
BT524
   Biotest AG
      2013   Phase 1;Phase 2   EUCTR2011-004154-25-IT   Egypt;Germany;Italy;Lebanon
BT595
   Biotest
      2016   Phase 3   NCT02810444   Germany;Hungary;Russian Federation;Spain;United States
   Biotest AG
      2017   Phase 3   EUCTR2015-003652-52-GB   Germany;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003652-52-ES   Germany;Hungary;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003652-52-DE   Germany;Russian Federation;Spain;United Kingdom;United States
BT681
   Biotest AG
      2005   -   EUCTR2004-004465-15-HU   Germany;Hungary
      2005   -   EUCTR2004-004465-15-DE   Germany;Hungary
Busilvex
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
   medac Gesellschaft fuer klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-AT   Austria;Czech Republic;Germany;Italy;Poland
   medac Gesellschaft für klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-DE   Austria;Czech Republic;Germany;Italy;Poland
      2014   Phase 2   EUCTR2013-005508-33-CZ   Austria;Czech Republic;Germany;Italy;Poland
   medac GmbH
      2015   Phase 2   NCT02349906   Austria;Czech Republic;Czechia;Germany;Italy;Poland
      2015   Phase 2   EUCTR2013-005508-33-IT   Austria;Czech Republic;Germany;Italy;Poland
      2014   Phase 2   EUCTR2013-005508-33-PL   Austria;Czech Republic;Germany;Italy;Poland
Busilvex - 6 MG/ML - concentrato PER soluzione PER infusione - USO endovenoso - flaconcino - 10 ML 8 flaconcini
   Fondazione Telethon
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy
Busulfan
   Baylor College of Medicine
      2004   Phase 2   NCT00578643   United States
   Fairview University Medical Center
      2000   -   NCT00006056   United States
      2000   -   NCT00006054   United States
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2018   Phase 1/Phase 2   NCT03765632   United Kingdom
      2012   Phase 1/Phase 2   NCT01380990   United Kingdom
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2012   -   NCT01652092   United States
      2000   Phase 2/Phase 3   NCT00176878   United States
   National Center for Child Health and Development
      2017   -   JPRN-UMIN000030647   Japan
      2016   -   JPRN-UMIN000022688   Japan
   National Center for Child Heath and Development
      2018   Phase 1,2   JPRN-UMIN000030806   Japan
   National Institute of Allergy and Infectious Diseases (NIAID)
      2025   Phase 1/Phase 2   NCT06851767   United States
      2024   Phase 1/Phase 2   NCT06325709   United States
      2022   Phase 1/Phase 2   NCT05463133   United States
      2019   Early Phase 1   NCT03910452   United States
      2015   Phase 1/Phase 2   NCT02629120   United States
      2014   Phase 1/Phase 2   NCT02282904   United States
      2012   Phase 1/Phase 2   NCT03315078   United States
      2012   Phase 1/Phase 2   NCT01306019   United States
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
   Sakaguchi Hirotoshi
      2018   Phase 2   JPRN-jRCTs031180398   Japan;None (Japan only)
   Seoul National University Hospital
      2011   Phase 1/Phase 2   NCT01338675   Korea, Republic of
   St. Jude Children's Research Hospital
      2016   Phase 1/Phase 2   NCT01512888   United States
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States
      2000   Phase 1/Phase 2   NCT00305708   United States
   medac Gesellschaft fuer klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-AT   Austria;Czech Republic;Germany;Italy;Poland
   medac Gesellschaft für klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-DE   Austria;Czech Republic;Germany;Italy;Poland
      2014   Phase 2   EUCTR2013-005508-33-CZ   Austria;Czech Republic;Germany;Italy;Poland
   medac GmbH
      2015   Phase 2   EUCTR2013-005508-33-IT   Austria;Czech Republic;Germany;Italy;Poland
      2014   Phase 2   EUCTR2013-005508-33-PL   Austria;Czech Republic;Germany;Italy;Poland
Busulfan test dose
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States
Busulfan, cyclophosphamide, ATG, gcsf
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2/Phase 3   NCT00176852   United States
Busulfan, fludarabine, ATG, TLI
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2/Phase 3   NCT00176852   United States
BW-20805
   Shanghai Argo Biopharmaceutical Co., Ltd.
      2025   Phase 2   NCT06846398   China;Germany;United States
C-1-esterase
   Penn State University
      2010   Phase 4   NCT01151735   -
C01eb19
   Jerini AG
      2010   Phase 3   EUCTR2008-000071-25-FR   Austria;Denmark;France;Germany;Italy;Spain;United Kingdom
      2010   -   EUCTR2008-000071-25-DK   Austria;Denmark;France;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-000071-25-GB   Austria;Denmark;France;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-000071-25-DE   Austria;Denmark;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-000071-25-AT   Austria;Denmark;France;Italy;Spain;United Kingdom
C1 esterase inhibitor
   CSL Behring
      2010   -   NCT01108848   Denmark;Germany;Switzerland;United States
      2005   Phase 3   NCT00292981   Canada;United States
      2005   Phase 2/Phase 3   NCT00168103   Argentina;Australia;Bulgaria;Canada;Czech Republic;Hungary;Israel;Macedonia, The Former Yugoslav Republic of;Poland;Romania;Russian Federation;Spain;Sweden;United Kingdom;United States
   CSL Behring GmbH
      2014   -   EUCTR2013-000916-10-ES   Argentina;Australia;Canada;Czech Republic;European Union;Hungary;Italy;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-000916-10-CZ   Argentina;Australia;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Spain;Switzerland;United Kingdom;United States
      2013   -   EUCTR2013-000916-10-IT   Argentina;Australia;Canada;Czech Republic;European Union;Hungary;Italy;Spain;United Kingdom;United States
      2013   -   EUCTR2013-000916-10-HU   Argentina;Australia;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Spain;Switzerland;United Kingdom;United States
      2013   Phase 3   EUCTR2013-000916-10-GB   Argentina;Australia;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Spain;Switzerland;United Kingdom;United States
   Shire
      2006   Phase 3   NCT00462709   United States
      2006   Phase 3   NCT00438815   United States
      2006   Phase 1   NCT00432510   United States
      2005   Phase 3   NCT01005888   United States
      2005   Phase 3   NCT00289211   United States
C1 esterase inhibitor [human] liquid
   Shire
      2015   Phase 3   NCT02584959   Canada;Germany;Hungary;Israel;Romania;Spain;United States
C1 esterase inhibitor concentrate
   ZLB Behring GmbH
      -   -   EUCTR2005-003139-38-Outside-EU/EEA   Canada;United States
C1 esterase inhibitor concentrate, human, pasteurized
   CSL Behring GmbH
      2007   -   EUCTR2004-001186-17-BG   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2004-001186-17-SE   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2004-001186-17-CZ   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
   ZLB Behring GmbH
      2005   Phase 3   EUCTR2004-001186-17-HU   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
      2005   -   EUCTR2004-001186-17-GB   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-001186-17-ES   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
C1 esterase inhibitor human
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2020   Phase 2   EUCTR2019-001693-28-DE   Belarus;Bulgaria;Czech Republic;Germany;Hungary;Poland;Russian Federation;Serbia;Ukraine
C1 esterase inhibitor liquid FOR injection
   Shire ViroPharma, Inc.
      2016   Phase 3   EUCTR2015-002478-19-HU   Canada;Germany;Hungary;Israel;Romania;Spain;United States
      2016   Phase 3   EUCTR2015-002478-19-ES   Canada;Germany;Hungary;Israel;Romania;Spain;United States
      2016   Phase 3   EUCTR2015-002478-19-DE   Canada;Germany;Hungary;Israel;Romania;Spain;United States
C1 inhibitor
   Shire
      2009   Phase 4   NCT00914966   United States
C1 inhibitor concentrate
   Sanquin
      2005   Phase 2   NCT00119431   Netherlands
C1-esterase inhibitor
   CSL BEHRING GMBH
      2015   Phase 3   EUCTR2014-001054-42-IT   Australia;Canada;Czech Republic;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
   CSL Behring
      2014   Phase 3   NCT02316353   Australia;Canada;Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Romania;Spain;United Kingdom;United States
   CSL Behring GmbH
      2015   Phase 3   EUCTR2014-001054-42-HU   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-001054-42-GB   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-001054-42-ES   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-001054-42-DE   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-001054-42-CZ   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
   IMMUNOe Research Centers
      2018   Phase 4   NCT03576469   United States
   Johann Wolfgang Goethe University Hospitals
      2008   Phase 3   NCT00748202   Germany
C1-esterase inhibitor - single intravenous dose
   CSL Behring
      2012   Phase 1/Phase 2   NCT01576523   Germany;United States
C1-esterase inhibitor - subcutaneous high dose
   CSL Behring
      2012   Phase 1/Phase 2   NCT01576523   Germany;United States
C1-esterase inhibitor - subcutaneous LOW dose
   CSL Behring
      2012   Phase 1/Phase 2   NCT01576523   Germany;United States
C1-esterase inhibitor - subcutaneous medium dose
   CSL Behring
      2012   Phase 1/Phase 2   NCT01576523   Germany;United States
C1-esterase-inhibitor
   CSL Behring GmbH
      2013   -   EUCTR2010-024242-30-BG   Bulgaria;Hungary;Poland
      2011   -   EUCTR2010-024242-30-PL   Bulgaria;Hungary;Poland
      2011   Phase 4   EUCTR2010-024242-30-HU   Bulgaria;Hungary;Poland
   Fachbereich Medizin der Johann Wolfgang Goethe-Universität Frankfurt/M.
      2008   -   EUCTR2008-000654-12-DE   Germany
C1-INH
   IMMUNOe Research Centers
      2018   Phase 4   NCT03576469   United States
Campath -1H
   Baylor College of Medicine
      2007   Phase 1/Phase 2   NCT00579137   United States
Campath 1H
   Masonic Cancer Center, University of Minnesota
      2007   Phase 2/Phase 3   NCT00455312   United States
Campath, fludarabine, cyclophosphamide
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2/Phase 3   NCT00176852   United States
Campath-1H
   Baylor College of Medicine
      2000   Phase 2   NCT00368355   United States
Catapresan 75, tabletten
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany
CD3/CD19 NEG allogeneic BMT
   National Institute of Allergy and Infectious Diseases (NIAID)
      2017   Phase 1/Phase 2   NCT03330795   United States
CD3/CD19 negative allogeneic hematopoietic stem cells
   Paul Szabolcs
      2013   Phase 1/Phase 2   NCT01852370   United States
CD34 stem cell selection therapy
   Diane George
      2013   Phase 1/Phase 2   NCT01966367   United States
CD34+ cell enriched stem cell graft
   University of Florida
      2025   -   NCT06731036   -
CD34+ hscs transduced with THE lentivirus vector, VSV-G pseudotyped CL20-4I-EF1A-H?C-OPT
   National Institute of Allergy and Infectious Diseases (NIAID)
      2012   Phase 1/Phase 2   NCT03315078   United States
CD34+cells
   Rocket Pharmaceuticals, Inc.
      2020   Phase 1;Phase 2   EUCTR2020-000517-33-GB   Spain;United Kingdom;United States
      2018   Phase 1   EUCTR2018-002680-26-ES   Spain
CDZ173
   NOVARTIS PHARMA SERVICES AG
      2018   Phase 2;Phase 3   EUCTR2016-000468-41-IT   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
   Novartis Pharma Services AG
      2021   Phase 2;Phase 3   EUCTR2016-000468-41-FR   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2016-000468-41-GB   Belarus;Czech Republic;Czechia;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2016-000468-41-IE   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
   Pharming Technologies B.V.
      2016   Phase 2;Phase 3   EUCTR2016-000468-41-NL   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
      2016   Phase 2;Phase 3   EUCTR2016-000468-41-CZ   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2016-000468-41-DE   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
CE1145
   AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
      2013   -   EUCTR2010-019670-32-IT   Italy
   CSL Behring GmbH
      2013   -   EUCTR2010-024242-30-BG   Bulgaria;Hungary;Poland
      2011   -   EUCTR2010-024242-30-PL   Bulgaria;Hungary;Poland
      2011   Phase 4   EUCTR2010-024242-30-HU   Bulgaria;Hungary;Poland
      2007   -   EUCTR2004-001186-17-BG   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2004-001186-17-SE   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2004-001186-17-CZ   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
   ZLB Behring GmbH
      2005   Phase 3   EUCTR2004-001186-17-HU   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
      2005   -   EUCTR2004-001186-17-GB   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-001186-17-ES   Bulgaria;Czech Republic;Hungary;Spain;Sweden;United Kingdom
      -   -   EUCTR2005-003139-38-Outside-EU/EEA   Canada;United States
Chemotherapy, intrathecal chemotherapy, steroid therapy
   St. Jude Children's Research Hospital
      2002   -   NCT00187057   United States
Cinryze
   Shire
      2010   Phase 2   NCT01095510   Germany;Hungary;United States
      2010   Phase 2   NCT01095497   United States
   Shire ViroPharma Incorporated
      2014   Phase 3   EUCTR2013-002453-29-GB   Germany;Italy;Mexico;Romania;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002453-29-DE   Germany;Mexico;Romania;United Kingdom;United States
      2012   -   EUCTR2012-000083-24-SE   Germany;Hungary;Spain;Sweden;United States
   ViroPharma Incorporated
      2014   Phase 3   EUCTR2013-002453-29-RO   Argentina;Germany;Italy;Mexico;Romania;Spain;United Kingdom;United States
      2012   -   EUCTR2012-000083-24-HU   Germany;Hungary;Spain;Sweden
      2012   Phase 2   EUCTR2012-000083-24-ES   Germany;Hungary;Spain;Sweden
      2012   -   EUCTR2012-000083-24-DE   Germany;Hungary;Spain;Sweden;United States
      2012   -   EUCTR2011-000369-11-DE   Germany;Hungary;United States
      2011   -   EUCTR2011-000369-11-HU   Germany;Hungary;United States
      -   Phase 3   EUCTR2013-002453-29-IT   Argentina;Germany;Italy;Mexico;Romania;Spain;United Kingdom;United States
Cinryze 1000
   Shire
      2014   Phase 3   NCT02052141   Argentina;Germany;Israel;Italy;Mexico;Romania;United Kingdom;United States
Cinryze 1000 U
   Shire
      2016   Phase 3   NCT02865720   Japan
Cinryze 500
   Shire
      2014   Phase 3   NCT02052141   Argentina;Germany;Israel;Italy;Mexico;Romania;United Kingdom;United States
Cinryze 500 U
   Shire
      2016   Phase 3   NCT02865720   Japan
Cinryze with rhuph20
   Shire
      2013   Phase 2   NCT01756157   Germany;Spain;Sweden;United States
      2011   Phase 2   NCT01426763   United States
CL20-I4-EF1A-H?C-OPT
   St. Jude Children's Research Hospital
      2016   Phase 1/Phase 2   NCT01512888   United States
Clinimacs
   St. Jude Children's Research Hospital
      2016   Phase 1/Phase 2   NCT01512888   United States
Clonidinhydrochlorid
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany
Code ATC:L01xc04
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 1;Phase 2   EUCTR2014-005585-30-FR   France
Collection OF samples
   Institut National de la Santé Et de la Recherche Médicale, France
      2021   -   NCT04902807   -
Complement C1 esterase inhibitor
   CSL Behring GmbH
      2015   Phase 3   EUCTR2014-001054-42-HU   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-001054-42-GB   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-001054-42-ES   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-001054-42-DE   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-001054-42-CZ   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
   Shire ViroPharma Incorporated
      2014   Phase 3   EUCTR2013-002453-29-GB   Germany;Italy;Mexico;Romania;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002453-29-DE   Germany;Mexico;Romania;United Kingdom;United States
      2012   -   EUCTR2012-000083-24-SE   Germany;Hungary;Spain;Sweden;United States
   Shire ViroPharma, Inc.
      2016   Phase 3   EUCTR2015-002478-19-HU   Canada;Germany;Hungary;Israel;Romania;Spain;United States
      2016   Phase 3   EUCTR2015-002478-19-ES   Canada;Germany;Hungary;Israel;Romania;Spain;United States
      2016   Phase 3   EUCTR2015-002478-19-DE   Canada;Germany;Hungary;Israel;Romania;Spain;United States
   ViroPharma Incorporated
      2014   Phase 3   EUCTR2013-002453-29-RO   Argentina;Germany;Italy;Mexico;Romania;Spain;United Kingdom;United States
      2012   -   EUCTR2012-000083-24-HU   Germany;Hungary;Spain;Sweden
      2012   -   EUCTR2012-000083-24-DE   Germany;Hungary;Spain;Sweden;United States
      -   Phase 3   EUCTR2013-002453-29-IT   Argentina;Germany;Italy;Mexico;Romania;Spain;United Kingdom;United States
   ZLB Behring GmbH
      -   -   EUCTR2005-003139-38-Outside-EU/EEA   Canada;United States
Computed tomography
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
   National Cancer Institute (NCI)
      2023   Phase 1/Phase 2   NCT05691491   United States
Conestat alfa
   PHARMING GROUP NV
      2015   Phase 2   EUCTR2014-002839-33-IT   Canada;Czech Republic;Czechia;Israel;Italy;North Macedonia;Poland;Romania;Serbia;United States
   PHARMING TECHNOLOGIES B.V.
      2011   Phase 2   EUCTR2011-000987-92-IT   Czech Republic;Germany;Hungary;Israel;Italy;Slovakia
      2011   Phase 3   EUCTR2011-000049-19-IT   Argentina;Hungary;Italy;Macedonia, the former Yugoslav Republic of;South Africa;United States
   Pharming Group NV
      2015   Phase 2   EUCTR2014-002839-33-CZ   Canada;Czech Republic;Israel;Italy;Macedonia, the former Yugoslav Republic of;Poland;Romania;Serbia;United States
   Pharming Technologies B.V.
      2015   Phase 2   EUCTR2011-000987-92-HU   Czech Republic;Germany;Hungary;Israel;Italy;Macedonia, the former Yugoslav Republic of;Slovakia
      2014   Phase 2   EUCTR2011-000987-92-SK   Czech Republic;Germany;Hungary;Israel;Italy;Slovakia
      2014   Phase 2   EUCTR2011-000987-92-CZ   Czech Republic;Germany;Hungary;Israel;Italy;Slovakia
      2011   Phase 2   EUCTR2011-000987-92-DE   Czech Republic;Germany;Hungary;Israel;Italy;Macedonia, the former Yugoslav Republic of;Poland;Romania;Slovakia
      2011   -   EUCTR2011-000049-19-HU   Hungary;Italy
Continuous glucose monitor
   Washington University School of Medicine
      2020   -   NCT04275479   United States
Covid-19 vaccine moderna
   Erasmus University Medical Center
      2021   Phase 4   EUCTR2021-000515-24-NL   Netherlands
Cryopreserved autologous CD34+ cells transduced with pcclchim-P47
   National Institute of Allergy and Infectious Diseases (NIAID)
      2024   Phase 1/Phase 2   NCT06253507   United States
Cryopreserved EFS-ADA LV transduced patient CD34+ cells
   Great Ormond Street Hospital for Children NHS Trust
      2017   Phase 2   EUCTR2017-001275-23-GB   United Kingdom
Cryopreserved G2scid lentiviral vector transduced patient CD34+ cells
   Great Ormond Street Hospital for Children NHS Trust
      2018   Phase 1   EUCTR2018-000673-68-GB   United Kingdom
CSL312
   CSL BEHRING GMBH
      -   Phase 3   EUCTR2020-000570-25-IT   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
   CSL Behring
      2023   Phase 3   NCT05819775   Australia;Canada;Germany;Israel;United States
      2021   Phase 3   NCT04739059   Australia;Canada;Czechia;Germany;Hong Kong;Hungary;Israel;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United States
      2021   Phase 3   NCT04656418   Canada;Germany;Hungary;Israel;Japan;Netherlands;United States
   CSL Behring LLC
      2021   Phase 3   EUCTR2020-000570-25-NL   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
      2021   Phase 3   EUCTR2020-000570-25-DE   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
      2020   Phase 3   EUCTR2020-000570-25-HU   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
      2018   Phase 2   EUCTR2018-000605-24-DE   Australia;Canada;Denmark;Germany;Israel;United States
CSL312 garadacimab
   CSL BEHRING GMBH
      -   Phase 3   EUCTR2020-003918-12-IT   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
   CSL Behring LLC
      2021   Phase 3   EUCTR2020-003918-12-NL   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003918-12-HU   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003918-12-DE   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003918-12-CZ   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
CSL830
   CSL BEHRING GMBH
      2015   Phase 3   EUCTR2014-001054-42-IT   Australia;Canada;Czech Republic;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
   CSL Behring
      2013   Phase 1   NCT01760343   Germany
   CSL Behring GmbH
      2015   Phase 3   EUCTR2014-001054-42-HU   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-001054-42-GB   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-001054-42-ES   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-001054-42-DE   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-001054-42-CZ   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Israel;Italy;Spain;United Kingdom;United States
      2014   -   EUCTR2013-000916-10-ES   Argentina;Australia;Canada;Czech Republic;European Union;Hungary;Italy;Spain;United Kingdom;United States
      2014   Phase 3   EUCTR2013-000916-10-CZ   Argentina;Australia;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Spain;Switzerland;United Kingdom;United States
      2013   -   EUCTR2013-000916-10-IT   Argentina;Australia;Canada;Czech Republic;European Union;Hungary;Italy;Spain;United Kingdom;United States
      2013   -   EUCTR2013-000916-10-HU   Argentina;Australia;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Spain;Switzerland;United Kingdom;United States
      2013   Phase 3   EUCTR2013-000916-10-GB   Argentina;Australia;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Spain;Switzerland;United Kingdom;United States
   Joshua S. Jacobs, MD
      2017   -   NCT03177005   -
CT scan
   Koneti Rao
      2008   Phase 1/Phase 2   NCT00605657   United States
Cultured thymus tissue
   Enzyvant Therapeutics GmBH
      1991   Phase 2   NCT00576407   United States
   Sumitomo Pharma Switzerland GmbH
      2022   -   NCT05329935   United States
      2010   -   NCT01220531   United States
Cultured thymus tissue implantation and parental parathyroid transplantation
   Enzyvant Therapeutics GmBH
      2005   Phase 1/Phase 2   NCT00579527   United States
Cultured thymus tissue implantation with parathyroid transplantation
   Enzyvant Therapeutics GmBH
      2004   Phase 2   NCT00576836   United States
Cutaquig
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2022   -   NCT05986734   Russian Federation
   Octapharma
      2019   Phase 3   NCT03939533   United States
Cuvitru
   Baxalta now part of Shire
      2018   -   NCT03716700   Canada
      2017   Phase 4   NCT03116347   Czechia;Denmark;France;Greece;Slovakia;Sweden;United Kingdom
Cuvitru 200 MG/ML solution FOR subcutaneous injection
   Baxalta US Inc.
      2019   Phase 4   EUCTR2016-003438-26-HU   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-SE   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-GR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-GB   Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-FR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-DK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-CZ   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      -   Phase 4   EUCTR2016-003438-26-SK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
Cyclophosphamide
   Baylor College of Medicine
      2004   Phase 2   NCT00578643   United States
      2000   Phase 2   NCT00368355   United States
   Capital Research Institute of Pediatrics
      2015   -   NCT03198195   -
   Fairview University Medical Center
      2000   -   NCT00006056   United States
      2000   -   NCT00006054   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
   Graduate Schoool, Dept. of Community Pediatrics, Perinatal and Maternal Medicine, Tokyo Medical and Dental University
      2015   -   JPRN-UMIN000019532   Japan
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2015   -   NCT02162420   United States
      2012   -   NCT01652092   United States
      2007   Phase 2/Phase 3   NCT00455312   United States
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT05463133   United States
      2019   Early Phase 1   NCT03910452   United States
      2015   Phase 1/Phase 2   NCT02629120   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
Cyclophosphamide dose level 1
   Children's Hospital Los Angeles
      2007   Phase 2   NCT02512679   -
Cyclophosphamide dose level 2
   Children's Hospital Los Angeles
      2007   Phase 2   NCT02512679   -
Cyclophosphamide dose level 3
   Children's Hospital Los Angeles
      2007   Phase 2   NCT02512679   -
Cyclophosphamide dose level 4
   Children's Hospital Los Angeles
      2007   Phase 2   NCT02512679   -
Cyclophosphamide post transplant
   National Institute of Allergy and Infectious Diseases (NIAID)
      2014   Phase 1/Phase 2   NCT02282904   United States
Cyclosporine
   Baylor College of Medicine
      2004   Phase 2   NCT00578643   United States
   Enzyvant Therapeutics GmBH
      2005   Phase 1/Phase 2   NCT00579527   United States
   Fairview University Medical Center
      2000   -   NCT00006056   United States
      2000   -   NCT00006054   United States
   Fred Hutchinson Cancer Research Center
      1997   Phase 1   NCT00008450   United States
   Sumitomo Pharma Switzerland GmbH
      2010   -   NCT01220531   United States
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States
Cyclosporine + BCX7353
   BioCryst Pharmaceuticals
      2017   Phase 1   NCT03136237   United Kingdom
Cyclosporins
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States
Cyklokapron
   JERINI AG
      2005   -   EUCTR2004-001540-71-IT   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
   Jerini AG
      2005   -   EUCTR2004-001540-71-SE   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-001540-71-IE   Austria;Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-AT   Austria;Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
Cyklokapron tablets
   Jerini AG
      2005   -   EUCTR2004-001540-71-LT   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-001540-71-GB   Austria;Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
Daclizumab
   Enzyvant Therapeutics GmBH
      2005   Phase 1/Phase 2   NCT00579527   United States
Danazol
   Boston Children's Hospital
      2009   Phase 1/Phase 2   NCT01001598   United States
   The University of Queensland
      2021   Phase 2   NCT04638517   Australia
Data collection
   Paul Szabolcs
      2020   -   NCT04528355   United States
Deucrictibant
   Academisch Medisch Centrum
      2023   Phase 2   EUCTR2022-003168-25-NL   Netherlands
   Pharvaris Netherlands B.V.
      2025   Phase 3   NCT06679881   Bulgaria;Hong Kong;Ireland;Poland;United Kingdom;United States
      2024   Phase 3   NCT06669754   Bulgaria;Canada;France;Hong Kong;Ireland;Japan;Korea, Republic of;Puerto Rico;Romania;Singapore;Slovakia;United Kingdom;United States
      2024   Phase 3   NCT06343779   Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Colombia;Czechia;France;Germany;Hong Kong;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;North Macedonia;Poland;Puerto Rico;Romania;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Turkey;United Kingdom;United States
      2021   Phase 2   NCT04618211   Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Deucrictibant high dose
   Pharvaris Netherlands B.V.
      2022   Phase 2   NCT05047185   Austria;Bulgaria;Canada;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
Deucrictibant LOW dose
   Pharvaris Netherlands B.V.
      2022   Phase 2   NCT05047185   Austria;Bulgaria;Canada;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
Deucrictibant selected dose
   Pharvaris Netherlands B.V.
      2022   Phase 2/Phase 3   NCT05396105   Argentina;Australia;Austria;Bulgaria;Canada;Czechia;France;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Puerto Rico;South Africa;Spain;Sweden;Turkey;United States
Dexametasone fosfato sodico
   ERYDEL S.P.A.
      2016   Phase 3   EUCTR2015-005241-31-IT   Australia;Belgium;Costa Rica;Germany;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States
Dexamethasone sodium phosphate
   ERYDEL S.P.A.
      2021   Phase 3   EUCTR2018-000338-36-IT   Australia;Belgium;Germany;India;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States
      2016   Phase 3   EUCTR2015-005241-31-IT   Australia;Belgium;Costa Rica;Germany;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States
   EryDel S.p.A.
      2020   Phase 3   EUCTR2018-000338-36-NO   Australia;Belgium;Germany;India;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States
      2020   Phase 3   EUCTR2018-000338-36-GB   Australia;Belgium;Germany;India;Israel;Norway;Poland;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000338-36-ES   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000338-36-DE   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-000338-36-BE   Australia;Belgium;Germany;India;Israel;Poland;Spain;United States
      2016   Phase 3   EUCTR2015-005241-31-NO   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States
      2016   Phase 3   EUCTR2015-005241-31-ES   Australia;Belgium;Costa Rica;Germany;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States
      2016   Phase 3   EUCTR2015-005241-31-DE   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States
      2016   Phase 3   EUCTR2015-005241-31-BE   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States
      -   Phase 3   EUCTR2018-000338-36-PL   Australia;Belgium;Germany;India;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States
      -   Phase 3   EUCTR2015-005241-31-PL   Australia;Belgium;Costa Rica;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;Turkey;United Kingdom;United States
   Quince Therapeutics S.p.A.
      2024   Phase 3   NCT06664853   Belgium;Denmark;Germany;Italy;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2024   Phase 3   NCT06193200   Belgium;Denmark;Germany;Italy;Norway;Poland;Spain;Switzerland;United Kingdom;United States
Dexamethasone, procarbazine
   St. Jude Children's Research Hospital
      2002   -   NCT00187057   United States
Dextrose, 5% IN water
   Grifols Therapeutics Inc.
      2002   Phase 3   NCT00220766   Canada;United States
Direct intravenous injection OF IVLV-X1 lentiviral vector
   Shenzhen Geno-Immune Medical Institute
      2024   Phase 1/Phase 2   NCT03217617   China
Donidalorsen
   IONIS PHARMACEUTICALS, INC.
      2023   Phase 3   EUCTR2022-000757-93-DE   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000757-93-PL   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000757-93-FR   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000757-93-BE   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-IT   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
   Ionis Pharmaceuticals, Inc.
      2023   -   NCT06415448   -
      2022   Phase 3   NCT05392114   Belgium;Bulgaria;Canada;France;Germany;Israel;Italy;Netherlands;Poland;Puerto Rico;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-PL   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-NL   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-ES   Belgium;Bulgaria;Canada;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-DK   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-BG   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-BE   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 3   NCT05139810   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2020   Phase 2   NCT04307381   Netherlands;United States
      2020   Phase 2   NCT04030598   Netherlands;United States
      -   Phase 3   EUCTR2021-002571-19-FR   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Donor mobilized pbsc infusion
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
Dose 1 OF BMN 331
   BioMarin Pharmaceutical
      2022   Phase 1/Phase 2   NCT05121376   Australia;Spain;United States
Dose 2 OF BMN 331
   BioMarin Pharmaceutical
      2022   Phase 1/Phase 2   NCT05121376   Australia;Spain;United States
Dose 3 OF BMN 331
   BioMarin Pharmaceutical
      2022   Phase 1/Phase 2   NCT05121376   Australia;Spain;United States
Dose 4 OF BMN 331
   BioMarin Pharmaceutical
      2022   Phase 1/Phase 2   NCT05121376   Australia;Spain;United States
Dose 5 OF BMN 331
   BioMarin Pharmaceutical
      2022   Phase 1/Phase 2   NCT05121376   Australia;Spain;United States
Dose 6 OF BMN 331
   BioMarin Pharmaceutical
      2022   Phase 1/Phase 2   NCT05121376   Australia;Spain;United States
Dose 7 OF BMN 331
   BioMarin Pharmaceutical
      2022   Phase 1/Phase 2   NCT05121376   Australia;Spain;United States
Doxorubicin, methotrexate, cyclophosphamide, L-asparaginase
   St. Jude Children's Research Hospital
      2002   -   NCT00187057   United States
DX-2930
   DYAX CORP.
      2016   Phase 3   EUCTR2015-005255-27-IT   Canada;Germany;Italy;Jordan;United Kingdom;United States
      -   Phase 3   EUCTR2015-003943-20-IT   Canada;Germany;Italy;United Kingdom
   Dyax Corp. (an indirect, wholly-owned subsidiary of Shire plc.)
      2016   Phase 3   EUCTR2015-005255-27-GB   Canada;Germany;Italy;Jordan;United Kingdom;United States
   Dyax Corp., (an indirect, wholly-owned subsidiary of Shire plc.)
      2016   Phase 3   EUCTR2015-005255-27-DE   Canada;Germany;Italy;Jordan;United Kingdom;United States
   Dyax Corp., an indirect, wholly-owned subsidiary of Shire plc.
      2016   Phase 3   EUCTR2015-003943-20-GB   Canada;Germany;Italy;Jordan;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003943-20-DE   Canada;Germany;Italy;Jordan;United Kingdom;United States
   Shire
      2016   Phase 3   NCT02741596   Canada;Germany;Israel;Italy;Puerto Rico;United Kingdom;United States
      2014   Phase 1   NCT02093923   Italy;Jordan;United States
      2013   Phase 1   NCT01923207   United States
   Shire (Shire is now part of Takeda)
      2020   Phase 3   EUCTR2018-002093-42-DE   Canada;Germany;Hungary;Spain;United States
      2019   Phase 3   EUCTR2018-002093-42-HU   Canada;Germany;Hungary;Spain;United States
      2019   Phase 3   EUCTR2018-002093-42-ES   Canada;Germany;Hungary;Spain;United States
DX-2930 - 150MG/4WK
   Shire
      2016   Phase 3   NCT02586805   Canada;Germany;Italy;Jordan;Puerto Rico;United Kingdom;United States
DX-2930 - 300MG/2WK
   Shire
      2016   Phase 3   NCT02586805   Canada;Germany;Italy;Jordan;Puerto Rico;United Kingdom;United States
DX-2930 - 300MG/4WK
   Shire
      2016   Phase 3   NCT02586805   Canada;Germany;Italy;Jordan;Puerto Rico;United Kingdom;United States
DX-88
   Dyax Corp
      2006   Phase 3   EUCTR2005-003819-71-GB   Belgium;Italy;United Kingdom
      2006   Phase 3   EUCTR2005-003819-71-BE   Belgium;Italy;United Kingdom
   Dyax Corp.
      -   Phase 2;Phase 3   EUCTR2010-022716-39-DE   Germany
   GENZYME
      2006   -   EUCTR2005-003819-71-IT   Italy;United Kingdom
   Shire
      2003   Phase 2   NCT01826916   -
DX2930
   Dyax Corp. (an indirect, wholly-owned subsidiary of Shire plc.)
      2016   Phase 3   EUCTR2015-005255-27-GB   Canada;Germany;Italy;Jordan;United Kingdom;United States
   Dyax Corp., (an indirect, wholly-owned subsidiary of Shire plc.)
      2016   Phase 3   EUCTR2015-005255-27-DE   Canada;Germany;Italy;Jordan;United Kingdom;United States
Ecallantide
   Dyax Corp
      2006   Phase 3   EUCTR2005-003819-71-GB   Belgium;Italy;United Kingdom
      2006   Phase 3   EUCTR2005-003819-71-BE   Belgium;Italy;United Kingdom
   Dyax Corp.
      -   Phase 2;Phase 3   EUCTR2010-022716-39-DE   Germany
   GENZYME
      2006   -   EUCTR2005-003819-71-IT   Italy;United Kingdom
   Shire
      2012   Phase 2/Phase 3   NCT01253382   -
      2010   -   NCT01059526   United States
      2007   Phase 3   NCT00457015   Canada;Jordan;United States
      2007   Phase 3   NCT00456508   Canada;Jordan;United States
      2005   Phase 3   NCT00262080   United States
      2003   Phase 2   NCT01826916   -
Ecallantide subcutaneous dosing
   NYU Langone Health
      2013   Phase 2   NCT01832896   United States
Echocardiography
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Efficacy OF gammagard subcutaneously AT week 12
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Efficacy OF gammagard subcutaneously AT week 24
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Efficacy OF gammagard subcutaneously AT week 36
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Efficacy OF gammagard subdermally AT week 12
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Efficacy OF gammagard subdermally AT week 24
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Efficacy OF gammagard subdermally AT week 36
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Elapegademase-lvlr
   Chiesi Farmaceutici S.p.A.
      2019   -   NCT03878069   United States
Eltrombopag
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2019   Phase 2   NCT04371939   Russian Federation
Emapalumab-izsg
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT05463133   United States
Empagliflozin
   Cliniques universitaires Saint-Luc
      2019   Phase 4   EUCTR2018-004191-35-BE   Belgium
   Hong Kong Children's Hospital
      2021   -   NCT04986735   -
   National Institute of Allergy and Infectious Diseases (NIAID)
      2021   Phase 1   NCT05078879   United States
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2023   Phase 2   NCT05960617   China
EN-374
   Ensoma
      2025   Phase 1/Phase 2   NCT06876363   -
EP2006
   Sandoz GmbH
      2011   -   EUCTR2011-001118-32-DE   Germany;Sweden
Erydex high dose DSP
   Quince Therapeutics S.p.A.
      2017   Phase 3   NCT02770807   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States
Erydex LOW dose DSP
   Quince Therapeutics S.p.A.
      2017   Phase 3   NCT02770807   Australia;Belgium;Germany;India;Israel;Italy;Norway;Poland;Spain;Tunisia;United Kingdom;United States
Estradiolvalerat
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany
Etoposide
   Fairview University Medical Center
      2000   -   NCT00006056   United States
      2000   -   NCT00006054   United States
Etoposide, cytarabine, mercaptopurine
   St. Jude Children's Research Hospital
      2002   -   NCT00187057   United States
EX vivo culture and transduction OF THE patient'S autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4I-EF1alpha-hgammac-OPT vector
   National Institute of Allergy and Infectious Diseases (NIAID)
      2012   Phase 1/Phase 2   NCT01306019   United States
EX-vivo GENE-therapy
   Hubert Serve, Prof., MD
      2013   Phase 1/Phase 2   NCT01906541   Germany
EZN-2279
   Leadiant Biosciences, Inc.
      2014   Phase 3   NCT01420627   United States
Facs analyses
   University Hospital, Strasbourg, France
      2018   -   NCT03427593   France
Factor xiia antagonist monoclonal antibody
   CSL BEHRING GMBH
      -   Phase 3   EUCTR2020-003918-12-IT   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2020-000570-25-IT   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
   CSL Behring
      2018   Phase 2   NCT03712228   Australia;Canada;Germany;Israel;United States
   CSL Behring LLC
      2021   Phase 3   EUCTR2020-000570-25-NL   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
      2021   Phase 3   EUCTR2020-000570-25-DE   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
      2020   Phase 3   EUCTR2020-000570-25-HU   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
      2018   Phase 2   EUCTR2018-000605-24-DE   Australia;Canada;Denmark;Germany;Israel;United States
Factor xiia inhibitor monoclonal antibody
   CSL Behring LLC
      2021   Phase 3   EUCTR2020-003918-12-NL   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003918-12-HU   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003918-12-DE   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003918-12-CZ   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
Fibrinogen concentrate from human plasma
   Biotest AG
      2013   Phase 1;Phase 2   EUCTR2011-004154-25-IT   Egypt;Germany;Italy;Lebanon
Filgrastim
   Fairview University Medical Center
      2000   -   NCT00006056   United States
   National Center for Research Resources (NCRR)
      1994   Phase 2   NCT00004787   -
   National Institute of Allergy and Infectious Diseases (NIAID)
      2025   Phase 1/Phase 2   NCT06851767   United States
      2024   Phase 1/Phase 2   NCT06325709   United States
   Sandoz GmbH
      2012   Phase 4   EUCTR2011-001118-32-SE   Germany;Sweden
Filgrastim hexal
   Sandoz GmbH
      2011   -   EUCTR2011-001118-32-DE   Germany;Sweden
Firazyr
   JERINI AG
      2010   -   EUCTR2008-000071-25-IT   Austria;Denmark;France;Italy;Spain;United Kingdom
   Jerini AG
      2010   Phase 3   EUCTR2008-000071-25-FR   Austria;Denmark;France;Germany;Italy;Spain;United Kingdom
      2010   -   EUCTR2008-000071-25-DK   Austria;Denmark;France;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-000071-25-GB   Austria;Denmark;France;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-000071-25-DE   Austria;Denmark;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-000071-25-AT   Austria;Denmark;France;Italy;Spain;United Kingdom
   Jerini US Inc
      2010   -   EUCTR2009-015606-19-LT   Hungary;Lithuania
      2010   Phase 3   EUCTR2009-015606-19-HU   Hungary;Lithuania
   Shire
      2019   -   NCT04057131   Japan
   Shire ViroPharma, Inc.
      2016   Phase 3   EUCTR2015-002478-19-HU   Canada;Germany;Hungary;Israel;Romania;Spain;United States
      2016   Phase 3   EUCTR2015-002478-19-ES   Canada;Germany;Hungary;Israel;Romania;Spain;United States
      2016   Phase 3   EUCTR2015-002478-19-DE   Canada;Germany;Hungary;Israel;Romania;Spain;United States
Firazyr (icatibant) 30 MG solution FOR injection IN PRE filled syringe
   Shire Orphan Therapies, Inc
      2012   Phase 4   EUCTR2011-003825-81-HU   Austria;Canada;Germany;Hungary;Israel;Italy;Spain;United States
      2012   Phase 4   EUCTR2011-003825-81-ES   Austria;Canada;Germany;Hungary;Israel;Italy;Spain;United States
      2012   Phase 4   EUCTR2011-003825-81-DE   Austria;Canada;Germany;Hungary;Israel;Italy;Spain;United States
   Shire Orphan Therapies, LLC
      2013   Phase 3   EUCTR2011-003825-81-AT   Argentina;Australia;Austria;Canada;Colombia;Germany;Hungary;Israel;Italy;Spain;United States
Firazyr 30 MG solucióN inyectable EN jeringa precargada
   Jerini AG
      2010   Phase 3   EUCTR2008-000071-25-ES   Austria;Denmark;France;Germany;Italy;Spain;United Kingdom
Firazyr 30 MG solution FOR injection IN PRE-filled syringe
   Pharvaris Netherlands B.V.
      2023   Phase 2;Phase 3   EUCTR2021-006906-58-IT   Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003445-11-IT   Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
Firazyr*SC 1SIR 30MG 3ml10MG/M
   SHIRE HUMAN GENETIC THERAPIES, INC.
      2012   -   EUCTR2011-003825-81-IT   Austria;Canada;Germany;Hungary;Israel;Italy;Spain;United States
Firazyr® 30 MG subcutaneous injection syringe: 3.0 ML×1 syringe
   Takeda Pharmaceutical Company Limited
      -   Phase 3   EUCTR2022-002627-35-Outside-EU/EEA   Japan
Fisetin
   Avni Joshi
      2023   Phase 2   NCT05593588   United States
Flebogamma 5% DIF
   Instituto Grifols, S.A.
      2008   Phase 4   NCT00634569   United States
Flow cytometry
   University Hospital Freiburg
      2007   -   NCT00499070   Austria;Belgium;Czech Republic;Denmark;Germany;Ireland;Italy;Netherlands;Poland;Spain;Switzerland
Fludarabina accord
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
Fludarabina teva - 25 MG/ML concentrato PER soluzione iniettabile O PER infusione 1 flaconcino DI vetro DA 2 ML
   Fondazione Telethon
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy
Fludarabine
   Baylor College of Medicine
      2007   Phase 1/Phase 2   NCT00579137   United States
      2004   Phase 2   NCT00578643   United States
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States
   Graduate Schoool, Dept. of Community Pediatrics, Perinatal and Maternal Medicine, Tokyo Medical and Dental University
      2015   -   JPRN-UMIN000019532   Japan
   Karolinska Universitetssjukhuset
      2018   Phase 2   EUCTR2018-001489-41-SE   Sweden;United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2015   -   NCT02162420   United States
      2007   Phase 2/Phase 3   NCT00455312   United States
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States
   National Center for Child Heath and Development
      2018   Phase 1,2   JPRN-UMIN000030806   Japan
   National Institute of Allergy and Infectious Diseases (NIAID)
      2014   Phase 1/Phase 2   NCT02282904   United States
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States
Fludarabine monophosphate
   Masonic Cancer Center, University of Minnesota
      2000   Phase 2/Phase 3   NCT00176878   United States
Fludarabine phosphate
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2012   Phase 2   NCT01529827   United States
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States
      2005   Phase 1   NCT00295971   United States
      2000   Phase 1/Phase 2   NCT00305708   United States
Fludarabine phosphate 30 MG
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States
Fludarabine phosphate 40 MG
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States
Fludarabine, busulfan, thymoglobulin
   The Korean Society of Pediatric Hematology Oncology
      2007   Phase 1/Phase 2   NCT00885833   Korea, Republic of
Fludarabine, melphalan, thiotepa
   St. Jude Children's Research Hospital
      2005   Phase 1   NCT00160355   United States
Food diary
   Washington University School of Medicine
      2020   -   NCT04275479   United States
Functional and antigenic C1 inhibitor
   HAE Global Registry Foundation
      2017   -   NCT03828279   Italy
Fxiia inhibitor monoclonal antibody
   CSL BEHRING GMBH
      -   Phase 3   EUCTR2020-003918-12-IT   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
      -   Phase 3   EUCTR2020-000570-25-IT   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
   CSL Behring LLC
      2021   Phase 3   EUCTR2020-003918-12-NL   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003918-12-HU   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003918-12-DE   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003918-12-CZ   Australia;Canada;Czech Republic;Czechia;Germany;Hong Kong;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Russian Federation;Spain;Taiwan;United Kingdom;United States
      2021   Phase 3   EUCTR2020-000570-25-NL   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
      2021   Phase 3   EUCTR2020-000570-25-DE   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
      2020   Phase 3   EUCTR2020-000570-25-HU   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
G-CSF
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2016   Phase 2   NCT03019809   Russian Federation
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2014   Phase 2/Phase 3   NCT02231879   United States
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
G1XCG
   Johann Wolfgang Goethe-University
      2013   Phase 1;Phase 2   EUCTR2012-001725-26-DE   Germany
G1xcgd transduced CD34+ cells
   GENETHON
      2013   Phase 1;Phase 2   EUCTR2012-000242-35-DE   France;Germany;Switzerland;United Kingdom
   Genethon
      2013   Phase 1;Phase 2   EUCTR2012-000242-35-GB   France;Germany;Switzerland;United Kingdom
Gadolinium FOR abdomen
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Gadolinium FOR lower back
   ASIS Corporation
      2016   Phase 1/Phase 2   NCT02123615   United States
Gammagard liquid
   Baxalta now part of Shire
      2017   Phase 3   NCT03277313   United States
Gammaglobulin
   Federal University of São Paulo
      2002   -   NCT00661401   Brazil
Gammanorm
   Octapharma
      2014   Phase 4   NCT02180763   France
Gammanorm 165 MG/ML
   Octapharma Pharmazeutika Produktionsges.m.b.H, Oberlaaer Strasse 235, A-1100 Vienna, Austria
      2015   Phase 3;Phase 4   EUCTR2014-003746-27-GB   Australia;Germany;United Kingdom
      2015   Phase 3;Phase 4   EUCTR2014-003746-27-DE   Australia;Germany;Italy;United Kingdom
Gammaplex
   Bio Products Laboratory
      2011   Phase 4   NCT01289847   Chile;Israel;United States
      2006   Phase 3   NCT00278954   United States
   Bio Products Laboratory Limited
      -   -   EUCTR2011-005679-18-Outside-EU/EEA   Chile;United States
Gammaplex 10
   Bio Products Laboratory
      2014   Phase 3   NCT01963143   Hungary;United Kingdom;United States
   Bio Products Laboratory Limited
      2014   Phase 3   EUCTR2013-002290-21-HU   Hungary;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002290-21-GB   Hungary;Israel;United Kingdom;United States
Gamunex-C
   Grifols Therapeutics Inc.
      2011   Phase 4   NCT01465958   United States
   Grifols Therapeutics LLC
      2020   Phase 3   NCT04561115   United States
Garadacimab
   CSL Behring
      2025   Phase 4   NCT06806657   United States
   CSL Behring LLC
      2021   Phase 3   EUCTR2020-000570-25-NL   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
      2021   Phase 3   EUCTR2020-000570-25-DE   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
      2020   Phase 3   EUCTR2020-000570-25-HU   Canada;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States
Gcsf
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2019   Phase 2   NCT03547830   Russian Federation
Gene therapy method FOR CGD
   National Institute of Allergy and Infectious Diseases (NIAID)
      1995   Phase 1   NCT00001476   United States
GENE-transduced autologous CD34+ stem cells
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00028236   United States
Genetically modified autologous blood stem cells
   Johann Wolfgang Goethe-University
      2013   Phase 1;Phase 2   EUCTR2012-001725-26-DE   Germany
Glycosade
   John Mitchell
      2013   -   NCT02054832   Canada
GNR-038, 100 ??/ KG
   AO GENERIUM
      2021   Phase 2/Phase 3   NCT04898309   Russian Federation
GNR-038, 100 ??/KG
   AO GENERIUM
      2020   Phase 1   NCT04557319   Russian Federation
GNR-038, 25 ??/KG
   AO GENERIUM
      2020   Phase 1   NCT04557319   Russian Federation
GNR-038, 50 ??/ KG
   AO GENERIUM
      2021   Phase 2/Phase 3   NCT04898309   Russian Federation
GNR-038, 50 ??/KG
   AO GENERIUM
      2020   Phase 1   NCT04557319   Russian Federation
GP91 grans
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1   NCT05189925   United States
Granulocyte colony stimulating factor
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
GTG003.08
   GENETHON
      -   Phase 1;Phase 2   EUCTR2009-011152-22-FR   France
GTX-102 high dose fast period 1 and period 2
   Acasti Pharma Inc.
      2022   Phase 1   NCT05531890   Canada
GTX-102 LOW dose fast period 1 and period 2
   Acasti Pharma Inc.
      2022   Phase 1   NCT05531890   Canada
GTX-102 medium dose fast period 1 and period 2
   Acasti Pharma Inc.
      2022   Phase 1   NCT05531890   Canada
GTX-102 medium dose slow period 1 and period 2
   Acasti Pharma Inc.
      2022   Phase 1   NCT05531890   Canada
Gvhd prophylaxis
   National Cancer Institute (NCI)
      2018   Phase 2   NCT03663933   United States
      2015   Phase 2   NCT02579967   United States
Haemocomplettan P
   CSL Behring GmbH
      2007   -   EUCTR2006-006023-39-IT   Italy
Haemocomplettan(R) P 1G/2G
   CSL Behring GmbH
      2011   -   EUCTR2007-004088-22-DE   Germany;Italy
Haploidentical hematopoietic cell transplantation
   Johns Hopkins All Children's Hospital
      2020   Phase 2   NCT04414046   United States
Hematopoetic stem cell transplantation
   University of Pittsburgh
      2012   -   NCT03333200   United States
Hematopoietic stem cell transplant
   Medical College of Wisconsin
      2013   Phase 2   NCT01998633   Canada;United States
Hematopoietic stem cell transplantation
   St. Jude Children's Research Hospital
      2005   Phase 1   NCT00160355   United States
Heparin
   University of Iowa
      1994   -   NCT00004694   -
Higher-volume C1-esterase inhibitor
   CSL Behring
      2014   Phase 3   NCT01912456   Australia;Canada;Czech Republic;Czechia;Hungary;Israel;Italy;Romania;Spain;United Kingdom;United States
Hizentra
   CSL Behring
      -   -   EUCTR2014-003609-14-Outside-EU/EEA   Japan
      -   -   EUCTR2014-003608-61-Outside-EU/EEA   Japan
      -   -   EUCTR2014-003409-13-Outside-EU/EEA   Japan
   CSL Behring AG
      2008   Phase 3   EUCTR2008-000830-30-GB   France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom
      -   -   EUCTR2014-003607-30-Outside-EU/EEA   United States
      -   -   EUCTR2014-003605-15-Outside-EU/EEA   United States
   CSL Behring LLC
      -   Phase 4   EUCTR2016-003799-33-Outside-EU/EEA   Canada;United States
   University of Alabama at Birmingham
      2024   Phase 4   NCT05193552   United States
   University of South Florida
      2010   -   NCT01354587   United States
HU-G012267
   Intellia Therapeutics, Inc.
      2023   Phase 1;Phase 2   EUCTR2021-001693-33-ES   Australia;Canada;France;Germany;Netherlands;New Zealand;Spain;United Kingdom;United States
      2023   Phase 1;Phase 2   EUCTR2021-001693-33-DE   Australia;France;Germany;Netherlands;New Zealand;Spain;United Kingdom
      2022   Phase 1;Phase 2   EUCTR2021-001693-33-NL   Australia;France;Germany;Netherlands;New Zealand;Spain;United Kingdom;United States
      2022   Phase 1;Phase 2   EUCTR2021-001693-33-FR   Australia;France;Germany;Netherlands;New Zealand;Spain;United Kingdom;United States
Human fibrinogen
   CSL Behring GmbH
      2011   -   EUCTR2007-004088-22-DE   Germany;Italy
Human fibrinogen concentrate
   Biotest AG
      2013   Phase 1;Phase 2   EUCTR2011-004154-25-IT   Egypt;Germany;Italy;Lebanon
Human immunoglobulin
   KEDRION S.P.A
      2021   Phase 3   EUCTR2020-001496-32-PT   Hungary;Italy;Portugal;Russian Federation;Slovakia
      2020   Phase 3   EUCTR2020-001496-32-SK   Hungary;Italy;Portugal;Russian Federation;Slovakia
      2020   Phase 3   EUCTR2020-001496-32-HU   Hungary;Italy;Portugal;Russian Federation;Slovakia
Human normal immunoglobulin
   Baxalta US Inc.
      2019   Phase 4   EUCTR2016-003438-26-HU   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-SE   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-GR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-GB   Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-FR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-DK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-CZ   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      -   Phase 4   EUCTR2016-003438-26-SK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
   Baxalta now part of Shire
      2011   Phase 2/Phase 3   NCT01412385   Austria;Germany;Hungary;Sweden;United Kingdom
   Baxter Innovations GmbH
      2012   -   EUCTR2012-000481-38-GB   Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom
      2012   Phase 2;Phase 3   EUCTR2010-019459-23-BE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2011   -   EUCTR2010-019459-23-SE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2011   Phase 2;Phase 3   EUCTR2010-019459-23-NL   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2011   -   EUCTR2010-019459-23-DE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2010-019459-23-HU   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2010-019459-23-GB   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2010-019459-23-AT   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
   Bio Products Laboratory Limited
      2014   Phase 3   EUCTR2013-002290-21-HU   Hungary;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002290-21-GB   Hungary;Israel;United Kingdom;United States
      -   -   EUCTR2011-005679-18-Outside-EU/EEA   Chile;United States
   Biotest AG
      2017   Phase 3   EUCTR2015-003652-52-GB   Germany;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003652-52-ES   Germany;Hungary;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003652-52-DE   Germany;Russian Federation;Spain;United Kingdom;United States
      2005   -   EUCTR2004-004465-15-HU   Germany;Hungary
      2005   -   EUCTR2004-004465-15-DE   Germany;Hungary
   CSL Behring
      -   -   EUCTR2014-003609-14-Outside-EU/EEA   Japan
      -   -   EUCTR2014-003608-61-Outside-EU/EEA   Japan
      -   -   EUCTR2014-003409-13-Outside-EU/EEA   Japan
   CSL Behring AG
      2008   Phase 3   EUCTR2008-000830-30-GB   France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom
      2008   Phase 3   EUCTR2008-000830-30-FR   France;Germany;Spain;Sweden;United Kingdom
      2008   -   EUCTR2008-000830-30-ES   France;Germany;Spain;Sweden;United Kingdom
      2008   -   EUCTR2008-000830-30-DE   France;Germany;Spain;Sweden;United Kingdom
      -   -   EUCTR2014-003607-30-Outside-EU/EEA   United States
      -   -   EUCTR2014-003605-15-Outside-EU/EEA   United States
      -   -   EUCTR2014-003772-23-Outside-EU/EEA   United States
   CSL Behring KK
      -   Phase 3   EUCTR2016-001631-12-Outside-EU/EEA   Japan
   CSL Behring LLC
      -   Phase 4   EUCTR2016-003799-33-Outside-EU/EEA   Canada;United States
   OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H.
      2023   Phase 1;Phase 3   EUCTR2020-004734-37-IT   Germany;Hungary;Italy;Netherlands;Poland;Slovakia;Ukraine;United States
   Octapharma AG
      2010   Phase 3   EUCTR2007-002611-27-FR   France;Germany;United Kingdom
   Octapharma Pharmazeutika Prod.Ges.m.b.H
      2023   Phase 1;Phase 3   EUCTR2020-004734-37-HU   Germany;Hungary;Italy;Netherlands;Poland;Slovakia;Ukraine;United States
      2021   Phase 1;Phase 3   EUCTR2020-004734-37-SK   Germany;Hungary;Italy;Poland;Russian Federation;Slovakia;Ukraine;United States
      2021   Phase 1;Phase 3   EUCTR2020-004734-37-DE   Germany;Hungary;Italy;Poland;Russian Federation;Slovakia;Ukraine;United States
      2017   Phase 1;Phase 3   EUCTR2013-003877-87-SK   Canada;Czech Republic;Hungary;Poland;Russian Federation;Slovakia;United States
      2015   Phase 3   EUCTR2013-003877-87-PL   Canada;Czech Republic;Hungary;Poland;Slovakia;United States
      2014   Phase 3   EUCTR2013-003877-87-HU   Canada;Czech Republic;Hungary;Poland;Slovakia;United States
      2014   Phase 1;Phase 3   EUCTR2013-003877-87-CZ   Canada;Czech Republic;Hungary;Poland;Slovakia;United States
      -   Phase 1;Phase 3   EUCTR2020-004734-37-PL   Germany;Hungary;Italy;Poland;Russian Federation;Slovakia;Ukraine;United States
   Sanquin Blood Supply Foundation
      2013   -   EUCTR2012-005727-32-NL   Netherlands
   UMC Utrecht
      2021   Phase 4   EUCTR2021-005001-26-NL   Netherlands
Human normal immunoglobulin FOR intravenous administration
   LFB SA
      2007   Phase 3   EUCTR2007-001410-17-FR   France
Human normal immunoglobulin FOR intravenous USE
   Biotest AG
      2010   -   EUCTR2010-019249-25-HU   Germany;Hungary
      2010   -   EUCTR2010-019249-25-DE   Germany;Hungary
   LFB BIOTECHNOLOGIES
      2013   Phase 3   EUCTR2010-023483-41-FR   France;Hungary
      2011   -   EUCTR2010-023483-41-HU   Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine
      2009   -   EUCTR2009-012036-32-FR   France
      -   -   EUCTR2010-023483-41-Outside-EU/EEA   Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine
Human normal immunoglobulin FOR subcutaneous administration
   CSL Behring
      2007   Phase 3   NCT00542997   France;Germany;Italy;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom
      2006   Phase 3   NCT00419341   United States
   LFB Biotechnologies
      2014   -   EUCTR2013-000620-34-GB   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2013-000620-34-IT   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2013-000620-34-HU   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2013-000620-34-DE   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom
Hyaluronoglucosaminidase
   Baxter Innovations GmbH
      2012   -   EUCTR2012-000481-38-GB   Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom
Hydroxyurea
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States
Hyqvia
   Baxalta now part of Shire
      2017   Phase 3   NCT03277313   United States
      2017   Phase 4   NCT03116347   Czechia;Denmark;France;Greece;Slovakia;Sweden;United Kingdom
      2015   -   NCT02593188   United States
   Centre Hospitalier Régional et Universitaire de Lille
      2016   Phase 3   EUCTR2016-001480-36-FR   France
   GWT-TUD GmbH
      2016   -   NCT03054181   France;Germany;Italy
   Takeda
      2023   Phase 2/Phase 3   NCT05755035   Czechia;Denmark;Germany;Netherlands;Poland;Slovakia;Spain;United States
Hyqvia 100 MG/ML solution FOR infusion FOR subcutaneous USE
   Baxalta US Inc.
      2019   Phase 4   EUCTR2016-003438-26-HU   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-SE   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-GR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-GB   Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-FR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-DK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-CZ   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      -   Phase 4   EUCTR2016-003438-26-SK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
I.V. recombinant human C1 inhibitor
   Pharming Technologies B.V.
      2004   Phase 2/Phase 3   NCT00262288   Netherlands
      2003   Phase 2   NCT00261053   Netherlands
I10E
   LFB BIOTECHNOLOGIES
      2013   Phase 3   EUCTR2010-023483-41-FR   France;Hungary
      2011   -   EUCTR2010-023483-41-HU   Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine
      -   -   EUCTR2010-023483-41-Outside-EU/EEA   Czech Republic;France;Hungary;Lithuania;Poland;Serbia;Ukraine
IB 1001
   IntraBio Ltd.
      2019   Phase 2   EUCTR2018-004407-39-GB   Germany;United Kingdom;United States
IB1001
   IntraBio Inc
      2020   Phase 2   NCT03759678   Germany;Spain;United Kingdom;United States
   IntraBio Ltd
      2020   Phase 2   EUCTR2018-004407-39-DE   Germany;Spain;United Kingdom;United States
   IntraBio Ltd.
      2019   Phase 2   EUCTR2018-004407-39-GB   Germany;United Kingdom;United States
Ibuprofen
   IRCCS San Raffaele
      2015   Phase 2   NCT03055247   Italy
   Ospedale San Raffaele
      2015   Phase 2   EUCTR2015-002356-27-IT   Italy
Icaspase9-transduced T cells
   Baylor College of Medicine
      2011   Phase 1   NCT01494103   United States
Icatibant
   Jerini AG
      2010   Phase 3   EUCTR2008-000071-25-ES   Austria;Denmark;France;Germany;Italy;Spain;United Kingdom
   Jerini US Inc
      2010   Phase 3   EUCTR2009-015606-19-HU   Hungary;Lithuania
   Massachusetts General Hospital
      2011   Phase 4   NCT01457430   United States
   Pharvaris Netherlands B.V.
      2023   Phase 2;Phase 3   EUCTR2021-006906-58-IT   Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003445-11-IT   Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
   Shire
      2015   Phase 3   NCT03888755   Japan
      2014   Phase 1   NCT02045264   United States
      2012   Phase 3   NCT01386658   Argentina;Australia;Austria;Canada;Colombia;Germany;Hungary;Israel;Italy;Spain;United States
      2009   Phase 3   NCT00997204   Argentina;Austria;Denmark;France;Germany;Israel;Italy;Spain;Switzerland;United Kingdom
      2009   Phase 3   NCT00912093   Australia;Canada;Hungary;Israel;Romania;Russian Federation;South Africa;Ukraine;United States
      2005   Phase 3   NCT00500656   Italy
      2004   Phase 3   NCT00097695   United States
   Shire ViroPharma, Inc.
      2016   Phase 3   EUCTR2015-002478-19-HU   Canada;Germany;Hungary;Israel;Romania;Spain;United States
      2016   Phase 3   EUCTR2015-002478-19-ES   Canada;Germany;Hungary;Israel;Romania;Spain;United States
      2016   Phase 3   EUCTR2015-002478-19-DE   Canada;Germany;Hungary;Israel;Romania;Spain;United States
   Takeda
      2022   -   NCT05509569   Japan;Jordan
Icatibant acetate
   JERINI AG
      2010   -   EUCTR2008-000071-25-IT   Austria;Denmark;France;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-001540-71-IT   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
   Jerini AG
      2010   Phase 3   EUCTR2008-000071-25-FR   Austria;Denmark;France;Germany;Italy;Spain;United Kingdom
      2010   -   EUCTR2008-000071-25-DK   Austria;Denmark;France;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-000071-25-GB   Austria;Denmark;France;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-000071-25-DE   Austria;Denmark;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-000071-25-AT   Austria;Denmark;France;Italy;Spain;United Kingdom
   Jerini US Inc
      2010   -   EUCTR2009-015606-19-LT   Hungary;Lithuania
   SHIRE HUMAN GENETIC THERAPIES, INC.
      2012   -   EUCTR2011-003825-81-IT   Austria;Canada;Germany;Hungary;Israel;Italy;Spain;United States
   Shire Orphan Therapies, Inc
      2012   Phase 4   EUCTR2011-003825-81-HU   Austria;Canada;Germany;Hungary;Israel;Italy;Spain;United States
      2012   Phase 4   EUCTR2011-003825-81-ES   Austria;Canada;Germany;Hungary;Israel;Italy;Spain;United States
      2012   Phase 4   EUCTR2011-003825-81-DE   Austria;Canada;Germany;Hungary;Israel;Italy;Spain;United States
   Shire Orphan Therapies, LLC
      2013   Phase 3   EUCTR2011-003825-81-AT   Argentina;Australia;Austria;Canada;Colombia;Germany;Hungary;Israel;Italy;Spain;United States
   Takeda Pharmaceutical Company Limited
      -   Phase 3   EUCTR2022-002627-35-Outside-EU/EEA   Japan
Icatibant acetate solution FOR injection 10 MG/ML
   Jerini AG
      2005   -   EUCTR2004-001540-71-SE   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-LT   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-001540-71-IE   Austria;Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-HU   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-001540-71-GB   Austria;Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-DE   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-AT   Austria;Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
IFN-gamma
   National Institute of Allergy and Infectious Diseases (NIAID)
      2010   Phase 4   NCT01147042   United States
IG vena 50 G/L solution FOR infusion 100 ML vial + infusion SET
   Kedrion SpA
      2013   Phase 3   EUCTR2013-000961-36-DE   Germany;Italy
IGG next generation
   Biotest
      2016   Phase 3   NCT02810444   Germany;Hungary;Russian Federation;Spain;United States
   Biotest AG
      2017   Phase 3   EUCTR2015-003652-52-GB   Germany;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003652-52-ES   Germany;Hungary;Russian Federation;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003652-52-DE   Germany;Russian Federation;Spain;United Kingdom;United States
IGHY10
   University Hospital, Lille
      2016   Phase 4   NCT02881437   France
Igng
   LFB BIOTECHNOLOGIES
      2009   -   EUCTR2009-012036-32-FR   France
   LFB SA
      2007   Phase 3   EUCTR2007-001410-17-FR   France
Igpro10
   CSL Behring KK
      -   Phase 3   EUCTR2016-001631-12-Outside-EU/EEA   Japan
Igpro20
   CSL Behring
      2017   Phase 4   NCT03033745   Canada;United States
      2008   Phase 3   NCT00751621   France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom
      2008   Phase 3   NCT00719680   United States
      2008   Phase 3   EUCTR2006-006745-13-PL   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom
   CSL Behring AG
      2008   -   EUCTR2008-000830-30-SE   France;Germany;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2008-000830-30-GB   France;Germany;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom
      2008   Phase 3   EUCTR2008-000830-30-FR   France;Germany;Spain;Sweden;United Kingdom
      2008   -   EUCTR2008-000830-30-ES   France;Germany;Spain;Sweden;United Kingdom
      2008   -   EUCTR2008-000830-30-DE   France;Germany;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-006745-13-SE   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-006745-13-GB   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-006745-13-FR   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2006-006745-13-ES   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-006745-13-DE   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom
      -   -   EUCTR2014-003607-30-Outside-EU/EEA   United States
   CSL Behring AG (casa madre)
      2007   -   EUCTR2006-006745-13-IT   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom
   CSL Behring LLC
      -   Phase 4   EUCTR2016-003799-33-Outside-EU/EEA   Canada;United States
Igsc 20% 150 MG/KG
   Grifols Therapeutics LLC
      2019   Phase 3   NCT03814798   United States
Igsc 20% daily push versus 2 times PER week pump
   Grifols Therapeutics LLC
      2019   Phase 3   NCT03814798   United States
Igsc 20% daily push versus every 2 weeks pump
   Grifols Therapeutics LLC
      2019   Phase 3   NCT03814798   United States
Igsc 20% daily push versus once A week pump
   Grifols Therapeutics LLC
      2019   Phase 3   NCT03814798   United States
Igsc 20% infusion
   Takeda
      2021   Phase 3   NCT04842643   Japan
Immune globulin intravenous
   Baxalta now part of Shire
      2020   Phase 3   NCT04346108   Japan
      2011   Phase 2/Phase 3   NCT01412385   Austria;Germany;Hungary;Sweden;United Kingdom
      2008   Phase 3   NCT00814320   Canada;United States
      2007   Phase 2/Phase 3   NCT00546871   United States
      2002   Phase 3   NCT00157079   United States
   Green Cross Corporation
      2011   Phase 3   NCT01406470   Canada;United States
   Grifols Therapeutics Inc.
      2006   Phase 2   NCT00389324   Canada;United States
   Prometic Biotherapeutics, Inc.
      2016   Phase 3   NCT02269163   United States
Immune globulin intravenous (human), 10% solution
   Baxalta now part of Shire
      2013   Phase 2/Phase 3   NCT01218438   Canada;United States
Immune globulin intravenous (human), 10% TVR (triple virally reduced) solution
   Baxalta now part of Shire
      2002   Phase 2   NCT00161993   Finland;Sweden
Immune globulin intravenous [human], 10% caprylate/chromatography purified
   Grifols Therapeutics Inc.
      2002   Phase 3   NCT00220766   Canada;United States
Immune globulin subcutaneous (human), 20% solution
   Baxalta now part of Shire
      2013   Phase 2/Phase 3   NCT01218438   Canada;United States
   Takeda
      2025   -   NCT06565078   Japan
Immune globulin subcutaneous (human), 20%, caprylate/chromatography purified
   Grifols Therapeutics Inc.
      2017   Phase 3   EUCTR2015-003290-15-HU   Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom
      2016   Phase 3   EUCTR2015-003290-15-GB   Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom
      2016   Phase 3   EUCTR2015-003290-15-FR   Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom
      2016   Phase 3   EUCTR2015-003290-15-ES   Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom
      2016   Phase 3   EUCTR2015-003290-15-DE   Australia;Czech Republic;France;Germany;Hungary;Poland;Spain;Sweden;United Kingdom
      2016   Phase 3   EUCTR2015-003290-15-CZ   Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom
      -   Phase 3   EUCTR2015-003290-15-PL   Czech Republic;France;Germany;Hungary;Poland;Spain;United Kingdom
Immunoglobulin G
   CSL Behring
      2008   Phase 3   EUCTR2006-006745-13-PL   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom
   CSL Behring AG
      -   -   EUCTR2014-003772-23-Outside-EU/EEA   United States
   CSL Limited
      2008   Phase 3   NCT00680446   Australia;New Zealand
   OCTAPHARMA AG
      2012   -   EUCTR2012-000792-16-HU   Czech Republic;Germany;Hungary
      2012   -   EUCTR2012-000792-16-DE   Czech Republic;Germany;Hungary
      2012   -   EUCTR2012-000792-16-CZ   Czech Republic;Germany;Hungary
      2010   -   EUCTR2009-011434-10-DE   Germany
      -   -   EUCTR2009-011434-10-Outside-EU/EEA   United States
   Octapharma AG
      -   -   EUCTR2011-005015-82-Outside-EU/EEA   United States
Immunoglobulina umana normale
   KEDRION S.P.A
      2020   Phase 3   EUCTR2020-001496-32-IT   Hungary;Italy;Portugal;Slovakia
Immunoglobulins, normal human
   CSL Behring AG (casa madre)
      2007   -   EUCTR2006-006745-13-IT   France;Germany;Italy;Poland;Spain;Sweden;United Kingdom
Immunologic technique
   University Hospital Freiburg
      2007   -   NCT00499070   Austria;Belgium;Czech Republic;Denmark;Germany;Ireland;Italy;Netherlands;Poland;Spain;Switzerland
Immunological diagnosis tests
   University Hospital, Lille
      2015   -   NCT02972281   France
Immunosuppression only conditioning
   National Cancer Institute (NCI)
      2018   Phase 2   NCT03663933   United States
Immunosuppression only conditioning -closed with amendment L
   National Cancer Institute (NCI)
      2015   Phase 2   NCT02579967   United States
IN vitro-treated peripheral blood stem cell transplantation
   University of California, San Francisco
      2005   Phase 1   NCT00295971   United States
Increlex
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 1/Phase 2   NCT00490100   United States
Infliximab
   National Institute of Allergy and Infectious Diseases (NIAID)
      2006   Phase 1/Phase 2   NCT00325078   United States
Infusion OF autologous EFS-ADA LV CD34+ cells
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2012   Phase 1/Phase 2   NCT01380990   United Kingdom
Infusion OF lentiviral TYF-CGD-modified autologous stem cells
   Shenzhen Geno-Immune Medical Institute
      2018   -   NCT03645486   China
INH
   Shire
      2009   Phase 4   NCT00914966   United States
Inhibidor DE LA esterasa C1 complemento
   ViroPharma Incorporated
      2012   Phase 2   EUCTR2012-000083-24-ES   Germany;Hungary;Spain;Sweden
Interferon gamma
   National Institute of Allergy and Infectious Diseases (NIAID)
      1999   Phase 2   NCT00001905   United States
Interferon gamma-1B
   University of Colorado, Denver
      2018   -   NCT03548818   United States
Interferon-gamma
   National Institute of Allergy and Infectious Diseases (NIAID)
      1992   Phase 4   NCT00001317   United States
Interleukin-2
   Soma Jyonouchi
      2008   Phase 1   NCT00774358   United States
Intratect
   Biotest AG
      2010   -   EUCTR2010-019249-25-HU   Germany;Hungary
      2010   -   EUCTR2010-019249-25-DE   Germany;Hungary
      2005   -   EUCTR2004-004465-15-HU   Germany;Hungary
      2005   -   EUCTR2004-004465-15-DE   Germany;Hungary
Intravenous immunoglobulin infusion
   Sanquin
      2013   Phase 3   NCT01985373   Netherlands
Intravenous infusion OF transduced cells
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2003   Phase 1/Phase 2   NCT01279720   United Kingdom
Isis 721744
   IONIS PHARMACEUTICALS, INC.
      2023   Phase 3   EUCTR2022-000757-93-DE   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000757-93-PL   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000757-93-FR   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000757-93-BE   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-IT   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
   Ionis Pharmaceuticals, Inc.
      2022   Phase 3   EUCTR2021-002571-19-PL   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-NL   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-ES   Belgium;Bulgaria;Canada;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-DK   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-BG   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002571-19-BE   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-000197-14-NL   Netherlands;United Kingdom;United States
      2020   Phase 2   EUCTR2019-001044-22-GB   Netherlands;United Kingdom;United States
      -   Phase 3   EUCTR2021-002571-19-FR   Belgium;Bulgaria;Canada;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Isolex 300I magnetic cell selector
   National Institute of Allergy and Infectious Diseases (NIAID)
      1995   Phase 1   NCT00001476   United States
Itraconazole
   National Institute of Allergy and Infectious Diseases (NIAID)
      1991   Phase 2   NCT00001280   United States
Ivig
   Azidus Brasil
      2024   Phase 3   NCT06089122   -
   Biotest AG
      2010   -   EUCTR2010-019249-25-HU   Germany;Hungary
      2010   -   EUCTR2010-019249-25-DE   Germany;Hungary
      2005   -   EUCTR2004-004465-15-HU   Germany;Hungary
      2005   -   EUCTR2004-004465-15-DE   Germany;Hungary
   Green Cross Corporation
      2011   Phase 3   NCT01406470   Canada;United States
   Kedrion S.p.A.
      2021   Phase 3   NCT04944979   Hungary;Italy;Portugal;Russian Federation;Slovakia;United States
      2019   Phase 3   NCT03961009   Canada;United States
      2012   Phase 3   NCT01581593   Canada;United States
   On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.
      2025   Phase 3   NCT06954441   -
   Sanquin Blood Supply Foundation
      2013   -   EUCTR2012-005727-32-NL   Netherlands
IVIG-PEG
   Grifols Therapeutics LLC
      2020   Phase 3   NCT04561115   United States
Jardiance
   Cliniques universitaires Saint-Luc
      2019   Phase 4   EUCTR2018-004191-35-BE   Belgium
JE049
   JERINI AG
      2005   -   EUCTR2004-001540-71-IT   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
   Jerini AG
      2010   Phase 3   EUCTR2008-000071-25-FR   Austria;Denmark;France;Germany;Italy;Spain;United Kingdom
      2010   -   EUCTR2008-000071-25-DK   Austria;Denmark;France;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-000071-25-GB   Austria;Denmark;France;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-000071-25-DE   Austria;Denmark;France;Germany;Italy;Spain;United Kingdom
      2009   -   EUCTR2008-000071-25-AT   Austria;Denmark;France;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-001540-71-SE   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-LT   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-001540-71-IE   Austria;Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-HU   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-001540-71-GB   Austria;Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-DE   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-AT   Austria;Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
   Shire Orphan Therapies, Inc
      2012   Phase 4   EUCTR2011-003825-81-HU   Austria;Canada;Germany;Hungary;Israel;Italy;Spain;United States
      2012   Phase 4   EUCTR2011-003825-81-ES   Austria;Canada;Germany;Hungary;Israel;Italy;Spain;United States
      2012   Phase 4   EUCTR2011-003825-81-DE   Austria;Canada;Germany;Hungary;Israel;Italy;Spain;United States
   Shire Orphan Therapies, LLC
      2013   Phase 3   EUCTR2011-003825-81-AT   Argentina;Australia;Austria;Canada;Colombia;Germany;Hungary;Israel;Italy;Spain;United States
JSP191
   National Institute of Allergy and Infectious Diseases (NIAID)
      2023   Early Phase 1   NCT05600907   United States
KIG10
   KEDRION S.P.A
      2021   Phase 3   EUCTR2020-001496-32-PT   Hungary;Italy;Portugal;Russian Federation;Slovakia
      2020   Phase 3   EUCTR2020-001496-32-SK   Hungary;Italy;Portugal;Russian Federation;Slovakia
      2020   Phase 3   EUCTR2020-001496-32-IT   Hungary;Italy;Portugal;Slovakia
      2020   Phase 3   EUCTR2020-001496-32-HU   Hungary;Italy;Portugal;Russian Federation;Slovakia
Kineret
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2015   Early Phase 1   NCT04136028   Russian Federation
Kiovig
   Baxalta now part of Shire
      2017   Phase 4   NCT03116347   Czechia;Denmark;France;Greece;Slovakia;Sweden;United Kingdom
   Baxter Innovations GmbH
      2012   Phase 2;Phase 3   EUCTR2010-019459-23-BE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2011   -   EUCTR2010-019459-23-SE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2011   Phase 2;Phase 3   EUCTR2010-019459-23-NL   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2011   -   EUCTR2010-019459-23-DE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2010-019459-23-HU   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2010-019459-23-GB   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2010-019459-23-AT   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
Kiovig 100 MG/ML solution FOR infusion
   Baxalta US Inc.
      2019   Phase 4   EUCTR2016-003438-26-HU   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-SE   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-GR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-GB   Czech Republic;Denmark;France;Greece;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-FR   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-DK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      2017   Phase 4   EUCTR2016-003438-26-CZ   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
      -   Phase 4   EUCTR2016-003438-26-SK   Czech Republic;Denmark;France;Greece;Hungary;Slovakia;Sweden;United Kingdom
   Baxter Innovations GmbH
      2012   -   EUCTR2012-000481-38-GB   Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom
KLH
   National Institute of Allergy and Infectious Diseases (NIAID)
      1999   Phase 2   NCT00001145   United States
KVD824
   KalVista Pharmaceuticals, Ltd.
      2021   Phase 2   NCT05055258   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Puerto Rico;United Kingdom;United States
      2019   Phase 1   NCT05178355   United Kingdom
KVD824 300 MG compresse A rilascio modificato
   KalVista Pharmaceuticals Ltd
      2021   Phase 2   EUCTR2021-000136-59-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
KVD824 300 MG modified release tablets
   Kalvista Pharmaceuticals Ltd
      2021   Phase 2   EUCTR2021-000136-59-HU   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000136-59-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000136-59-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000136-59-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
KVD824 hydrochloride
   KalVista Pharmaceuticals Ltd
      2021   Phase 2   EUCTR2021-000136-59-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
   Kalvista Pharmaceuticals Ltd
      2021   Phase 2   EUCTR2021-000136-59-HU   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000136-59-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000136-59-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000136-59-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
KVD824 immediate-release capsule
   KalVista Pharmaceuticals, Ltd.
      2020   Phase 1   NCT05118958   United Kingdom
KVD824 prototype 1 modified-release tablet
   KalVista Pharmaceuticals, Ltd.
      2020   Phase 1   NCT05118958   United Kingdom
KVD824 prototype 2 modified-release tablet
   KalVista Pharmaceuticals, Ltd.
      2020   Phase 1   NCT05118958   United Kingdom
KVD824 prototype 3 modified-release tablet
   KalVista Pharmaceuticals, Ltd.
      2020   Phase 1   NCT05118958   United Kingdom
KVD900
   KalVista Pharmaceuticals, Ltd.
      2019   Phase 2   NCT04208412   Austria;Czechia;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States
      2018   Phase 1   NCT04349800   United Kingdom
KVD900 100 MG film coated tablet
   KalVista Pharmaceuticals Ltd
      2019   Phase 2   EUCTR2018-004489-32-IT   Austria;Czechia;France;Germany;Hungary;Italy;Netherlands;Poland;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004489-32-GB   Austria;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Netherlands;United Kingdom;United States
   KalVista Pharmaceuticals Ltd.
      2019   Phase 2   EUCTR2018-004489-32-PL   Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004489-32-NL   Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004489-32-HU   Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom
      2019   Phase 2   EUCTR2018-004489-32-DE   Austria;Germany;Hungary;Italy;Netherlands;North Macedonia;Poland;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004489-32-AT   Austria;Germany;Hungary;Italy;Macedonia, the former Yugoslav Republic of;Netherlands;Poland;United Kingdom;United States
KVD900 150 MG
   KalVista Pharmaceuticals, Ltd.
      2024   Phase 3   NCT06467084   Canada;France;Germany;Israel;Italy;Japan;United States
KVD900 300 MG
   KalVista Pharmaceuticals, Ltd.
      2024   Phase 3   NCT06467084   Canada;France;Germany;Israel;Italy;Japan;United States
      2022   Phase 3   NCT05511922   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Israel;Japan;Netherlands;New Zealand;Romania;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   NCT05505916   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   NCT05259917   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Romania;Slovakia;Spain;United Kingdom;United States
KVD900 300 MG compressa rivestita CON film
   KalVista Pharmaceuticals Ltd
      2022   Phase 3   EUCTR2021-001226-21-IT   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
KVD900 300 MG film coated tablet
   KalVista Pharmaceuticals Ltd
      2023   Phase 3   EUCTR2021-001226-21-SK   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-001226-21-PT   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-001176-42-SK   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-001176-42-PT   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-001176-42-IT   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001226-21-PL   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001226-21-NL   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001226-21-IT   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001226-21-HU   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;North Macedonia;Poland;Romania;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001226-21-GR   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001226-21-ES   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;North Macedonia;Poland;Romania;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001226-21-DE   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-RO   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-PL   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-NL   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-GR   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-FR   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-BG   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-AT   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
KVD900 600 MG
   KalVista Pharmaceuticals, Ltd.
      2022   Phase 3   NCT05511922   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Israel;Japan;Netherlands;New Zealand;Romania;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   NCT05505916   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   NCT05259917   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Puerto Rico;Romania;Slovakia;Spain;United Kingdom;United States
KVD900 75 MG
   KalVista Pharmaceuticals, Ltd.
      2024   Phase 3   NCT06467084   Canada;France;Germany;Israel;Italy;Japan;United States
L-arginin-hydrochlorid-einmolar fresenius
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany
L-fucose
   AUG Therapeutics
      2022   Phase 3   NCT05462587   United States
   Orpha Labs
      2012   Phase 1/Phase 2   NCT03354533   -
Laboratory biomarker analysis
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
      1997   Phase 1   NCT00008450   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2012   Phase 2   NCT01529827   United States
Ladicell
   Rocket Pharmaceuticals, Inc.
      2020   Phase 1;Phase 2   EUCTR2020-000517-33-GB   Spain;United Kingdom;United States
      2018   Phase 1   EUCTR2018-002680-26-ES   Spain
Lanadelumab
   Charité - Universitätsmedizin Berlin Klinik für Dermatologie und Allergologie
      2019   Phase 2   EUCTR2018-004136-30-DE   Germany
   DYAX CORP.
      2016   Phase 3   EUCTR2015-005255-27-IT   Canada;Germany;Italy;Jordan;United Kingdom;United States
   Dyax Corp. (an indirect, wholly-owned subsidiary of Shire plc.)
      2016   Phase 3   EUCTR2015-005255-27-GB   Canada;Germany;Italy;Jordan;United Kingdom;United States
   Dyax Corp., (an indirect, wholly-owned subsidiary of Shire plc.)
      2016   Phase 3   EUCTR2015-005255-27-DE   Canada;Germany;Italy;Jordan;United Kingdom;United States
   Dyax Corp., an indirect, wholly-owned subsidiary of Shire plc.
      2016   Phase 3   EUCTR2015-003943-20-GB   Canada;Germany;Italy;Jordan;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003943-20-DE   Canada;Germany;Italy;Jordan;United Kingdom;United States
   Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
      2025   Phase 4   ChiCTR2500098307   China
   Shire
      2019   Phase 3   NCT04180163   Japan
      2019   Phase 3   NCT04070326   Canada;Germany;Hungary;Spain;United States
   Shire (Shire is now part of Takeda)
      2020   Phase 3   EUCTR2018-002093-42-DE   Canada;Germany;Hungary;Spain;United States
      2019   Phase 3   EUCTR2018-002093-42-HU   Canada;Germany;Hungary;Spain;United States
      2019   Phase 3   EUCTR2018-002093-42-ES   Canada;Germany;Hungary;Spain;United States
   Takeda
      2022   Phase 3   NCT05460325   China
      2022   -   NCT05397431   Japan
      -   Phase 3   EUCTR2023-001105-31-Outside-EU/EEA   China
Lanadelumab 150 MG
   Shire
      2020   -   NCT04583007   Canada;Germany;Hungary;Spain;United States
Lanadelumab 300 MG
   Shire
      2020   -   NCT04583007   Canada;Germany;Hungary;Spain;United States
Lapine T-lymphocyte immune globulin
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
Lemtrada
   Karolinska Universitetssjukhuset
      2018   Phase 2   EUCTR2018-001489-41-SE   Sweden;United States
Leniolisib
   NOVARTIS PHARMA SERVICES AG
      2018   Phase 2;Phase 3   EUCTR2016-000468-41-IT   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
   Novartis Pharma Services AG
      2021   Phase 2;Phase 3   EUCTR2016-000468-41-FR   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2016-000468-41-GB   Belarus;Czech Republic;Czechia;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2016-000468-41-IE   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
   Pharming Technologies B.V.
      2025   Phase 2   NCT06897358   United States
      2024   Phase 2   NCT06549114   United States
Leniolisib phosphate
   Pharming Technologies B.V.
      2016   Phase 2;Phase 3   EUCTR2016-000468-41-NL   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
      2016   Phase 2;Phase 3   EUCTR2016-000468-41-CZ   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2016-000468-41-DE   Belarus;Czech Republic;Czechia;France;Germany;Ireland;Italy;Netherlands;Russian Federation;United Kingdom;United States
Lenograstim
   Fondazione Telethon
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy
   Ospedale San Raffaele
      2015   Phase 2   EUCTR2015-002356-27-IT   Italy
Lentiviral G1xcgd gene therapy
   University of California, Los Angeles
      2015   Phase 1/Phase 2   NCT02234934   United States
Lentiviral gene transfer
   National Human Genome Research Institute (NHGRI)
      2013   Phase 1   NCT02022696   United States
Lentiviral vector transduced CD34+ cells
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2023   Phase 1/Phase 2   NCT05207657   United Kingdom
      2018   Phase 1   NCT03601286   United Kingdom
LFB-igsc
   LFB Biotechnologies
      2014   -   EUCTR2013-000620-34-GB   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2013-000620-34-IT   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2013-000620-34-HU   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom
      2013   -   EUCTR2013-000620-34-DE   France;Germany;Hungary;Italy;Poland;Ukraine;United Kingdom
LOW-volume C1-esterase inhibitor
   CSL Behring
      2014   Phase 3   NCT01912456   Australia;Canada;Czech Republic;Czechia;Hungary;Israel;Italy;Romania;Spain;United Kingdom;United States
Mabcampath
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 1;Phase 2   EUCTR2014-005585-30-FR   France
Mabthera
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
Mabthera - 2 fiale 100 MG 10 ML
   Fondazione Telethon
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy
Magnetic resonance imaging
   National Cancer Institute (NCI)
      2023   Phase 1/Phase 2   NCT05691491   United States
MAS825
   Novartis Pharma AG
      2021   Phase 2   EUCTR2020-003596-17-CZ   Canada;Czech Republic;Czechia;France;Italy;Japan;Spain;Türkiye;United States
   Novartis Pharmaceuticals
      2020   Phase 2   NCT04641442   Canada;Czechia;France;Italy;Japan;Spain;Turkey;United Kingdom;United States
   The Hospital for Sick Children
      2023   Phase 3   NCT06309823   Canada
Mavorixafor
   X4 PHARMACEUTICALS, INC.
      2020   Phase 3   EUCTR2019-001153-10-IT   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
   X4 Pharmaceuticals
      2019   Phase 3   NCT03995108   Australia;Austria;Denmark;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Turkey;United States
   X4 Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2019-001153-10-PL   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-NL   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-HU   Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-GB   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-FR   Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-ES   Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-DE   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-AT   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001153-10-DK   Australia;Austria;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
MBM-01
   Matrix Biomed, Inc.
      2021   Phase 2   NCT04887311   United States
Mctls
   Catherine Bollard
      2014   Phase 1   NCT02510404   United States
Medical history questionnaires
   Washington University School of Medicine
      2020   -   NCT04275479   United States
Melphalan
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2012   -   NCT01652092   United States
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
Mesna
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States
Messenger RNA encoding CAS9
   Intellia Therapeutics, Inc.
      2023   Phase 1;Phase 2   EUCTR2021-001693-33-ES   Australia;Canada;France;Germany;Netherlands;New Zealand;Spain;United Kingdom;United States
      2023   Phase 1;Phase 2   EUCTR2021-001693-33-DE   Australia;France;Germany;Netherlands;New Zealand;Spain;United Kingdom
      2022   Phase 1;Phase 2   EUCTR2021-001693-33-NL   Australia;France;Germany;Netherlands;New Zealand;Spain;United Kingdom;United States
      2022   Phase 1;Phase 2   EUCTR2021-001693-33-FR   Australia;France;Germany;Netherlands;New Zealand;Spain;United Kingdom;United States
Metformin
   NHS Tayside
      2016   Phase 4   NCT02733679   United Kingdom
Methotrexate
   Fairview University Medical Center
      2000   -   NCT00006056   United States
      2000   -   NCT00006054   United States
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States
Methylprednisolone
   Fairview University Medical Center
      2000   -   NCT00006054   United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2007   Phase 2/Phase 3   NCT00455312   United States
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States
Methylprednisolone or prednisolone
   Enzyvant Therapeutics GmBH
      2005   Phase 1/Phase 2   NCT00579527   United States
   Sumitomo Pharma Switzerland GmbH
      2010   -   NCT01220531   United States
Miltenyi clinimacs selection system
   St. Jude Children's Research Hospital
      2005   Phase 1   NCT00160355   United States
MMF
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States
Modified mixed meal tolerance test
   Washington University School of Medicine
      2020   -   NCT04275479   United States
Modified oral glucose tolerance test
   Washington University School of Medicine
      2020   -   NCT04275479   United States
Mozobil
   Fondazione Telethon
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy
   IRCCS San Raffaele
      2015   Phase 2   NCT03055247   Italy
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
   Ospedale San Raffaele
      2015   Phase 2   EUCTR2015-002356-27-IT   Italy
MTP 101-LF
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT05333471   United States
Multigated acquisition scan
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
MUNC-CD34
   Assistance Publique - Hôpitaux de Paris
      2025   Phase 1/Phase 2   NCT06736080   France
MUNC-T3
   Assistance Publique - Hôpitaux de Paris
      2025   Phase 1/Phase 2   NCT06736080   France
Mycophenolate mofetil
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States
   Enzyvant Therapeutics GmBH
      2005   Phase 1/Phase 2   NCT00579527   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
      1997   Phase 1   NCT00008450   United States
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
   Sumitomo Pharma Switzerland GmbH
      2010   -   NCT01220531   United States
Myeloablative conditioning-closed with amendment L
   National Cancer Institute (NCI)
      2015   Phase 2   NCT02579967   United States
Myeloablative preparative regimen
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States
Myelostim
   IRCCS San Raffaele
      2015   Phase 2   NCT03055247   Italy
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
Myelostim - 34 1 flaconcino liofilizzato 33.6 MIU + siringa preriempita solvente 1 ML
   Fondazione Telethon
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy
Myelostim 34 milions UI/ML - powder and solvent FOR solution FOR injection/infusion
   Ospedale San Raffaele
      2015   Phase 2   EUCTR2015-002356-27-IT   Italy
Myelostim 34 milions UI/ML, powder and solvent FOR solution FOR injection or infusion
   Ospedale San Raffaele
      2015   Phase 2   EUCTR2015-002356-27-IT   Italy
N-acetyl-L-leucine
   IntraBio Inc
      2025   Phase 3   NCT06673056   Germany;Slovakia;Spain;Switzerland;United Kingdom;United States
   IntraBio Ltd
      2020   Phase 2   EUCTR2018-004407-39-DE   Germany;Spain;United Kingdom;United States
   IntraBio Ltd.
      2019   Phase 2   EUCTR2018-004407-39-GB   Germany;United Kingdom;United States
Nanogam 100 MG/ML
   Sanquin Blood Supply Foundation
      2013   -   EUCTR2012-005727-32-NL   Netherlands
Nanogam® 50 MG/ML
   Sanquin Blood Supply Foundation
      2013   -   EUCTR2012-005727-32-NL   Netherlands
Navenibart
   Astria Therapeutics, Inc.
      2025   Phase 3   NCT06842823   Canada;United States
NDV-3A
   National Institute of Allergy and Infectious Diseases (NIAID)
      2016   Phase 2   NCT02996448   United States
Newgam
   OCTAPHARMA AG
      2010   -   EUCTR2009-011434-10-DE   Germany
      -   -   EUCTR2009-011434-10-Outside-EU/EEA   United States
   Octapharma
      2011   Phase 3   NCT01313507   United States
      2010   Phase 3   NCT01012323   United States
   Octapharma AG
      -   -   EUCTR2011-005015-82-Outside-EU/EEA   United States
Newnorm
   OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H.
      2023   Phase 1;Phase 3   EUCTR2020-004734-37-IT   Germany;Hungary;Italy;Netherlands;Poland;Slovakia;Ukraine;United States
   Octapharma
      2021   Phase 3   NCT04640142   Germany;Hungary;Italy;Poland;Slovakia;Ukraine;United States
   Octapharma Pharmazeutika Prod.Ges.m.b.H
      2023   Phase 1;Phase 3   EUCTR2020-004734-37-HU   Germany;Hungary;Italy;Netherlands;Poland;Slovakia;Ukraine;United States
      2021   Phase 1;Phase 3   EUCTR2020-004734-37-SK   Germany;Hungary;Italy;Poland;Russian Federation;Slovakia;Ukraine;United States
      2021   Phase 1;Phase 3   EUCTR2020-004734-37-DE   Germany;Hungary;Italy;Poland;Russian Federation;Slovakia;Ukraine;United States
      -   Phase 1;Phase 3   EUCTR2020-004734-37-PL   Germany;Hungary;Italy;Poland;Russian Federation;Slovakia;Ukraine;United States
Nicotinamide riboside
   The University of Queensland
      2024   -   NCT06324877   Australia
Nonmyeloablative allogeneic hematopoietic stem cell transplantation
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
      1997   Phase 1   NCT00008450   United States
Normal human immunoglobulin G
   CSL Behring AG
      2008   -   EUCTR2008-000830-30-SE   France;Germany;Spain;Sweden;United Kingdom
Normal saline IV administration
   Intellia Therapeutics
      2025   Phase 3   NCT06634420   Australia;Canada;France;Germany;Netherlands;New Zealand;South Africa;United Kingdom;United States
      2021   Phase 1/Phase 2   NCT05120830   Australia;France;Germany;Netherlands;New Zealand;United Kingdom
Norovirus -specific T-cell (NST) therapy
   Children's National Research Institute
      2022   Phase 1   NCT04691622   United States
Noxafil 40 MG/ML oral solution
   Radboud University Nijmegen Medical Centre
      2009   -   EUCTR2008-004518-28-GB   Netherlands;United Kingdom
      2008   -   EUCTR2008-004518-28-NL   Netherlands;United Kingdom
NTLA-2002
   Intellia Therapeutics
      2025   Phase 3   NCT06634420   Australia;Canada;France;Germany;Netherlands;New Zealand;South Africa;United Kingdom;United States
   Intellia Therapeutics, Inc.
      2023   Phase 1;Phase 2   EUCTR2021-001693-33-ES   Australia;Canada;France;Germany;Netherlands;New Zealand;Spain;United Kingdom;United States
      2023   Phase 1;Phase 2   EUCTR2021-001693-33-DE   Australia;France;Germany;Netherlands;New Zealand;Spain;United Kingdom
      2022   Phase 1;Phase 2   EUCTR2021-001693-33-NL   Australia;France;Germany;Netherlands;New Zealand;Spain;United Kingdom;United States
      2022   Phase 1;Phase 2   EUCTR2021-001693-33-FR   Australia;France;Germany;Netherlands;New Zealand;Spain;United Kingdom;United States
Nutropinaq 10MG/2ML (30 I.E.) injektionsllösung
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany
OCTA-C1-INH
   Octapharma
      2024   Phase 3   NCT06361537   Armenia;Bulgaria;Mexico;Montenegro;Peru;Romania;Serbia;Ukraine;United States
   Octapharma Pharmazeutika Produktionsges.m.b.H.
      2020   Phase 2   EUCTR2019-001693-28-DE   Belarus;Bulgaria;Czech Republic;Germany;Hungary;Poland;Russian Federation;Serbia;Ukraine
Octagam
   OCTAPHARMA AG
      2012   -   EUCTR2012-000792-16-HU   Czech Republic;Germany;Hungary
      2012   -   EUCTR2012-000792-16-DE   Czech Republic;Germany;Hungary
      2012   -   EUCTR2012-000792-16-CZ   Czech Republic;Germany;Hungary
   Octapharma
      2009   Phase 3   NCT00811174   Austria
   Octapharma AG
      2010   Phase 3   EUCTR2007-002611-27-GB   France;Germany;United Kingdom
      2010   Phase 3   EUCTR2007-002611-27-FR   France;Germany;United Kingdom
      2008   -   EUCTR2007-002611-27-DE   France;Germany;United Kingdom
Octanorm
   Octapharma
      2017   Phase 3   NCT03988426   Russian Federation
      2016   Phase 3   NCT03907241   Canada;United States
      2016   Phase 3   NCT02627300   Canada;United States
      2014   Phase 3   NCT01888484   Canada;Czech Republic;Czechia;Hungary;Poland;Russian Federation;Slovakia;United States
   Octapharma Pharmazeutika Prod.Ges.m.b.H
      2017   Phase 1;Phase 3   EUCTR2013-003877-87-SK   Canada;Czech Republic;Hungary;Poland;Russian Federation;Slovakia;United States
      2015   Phase 3   EUCTR2013-003877-87-PL   Canada;Czech Republic;Hungary;Poland;Slovakia;United States
      2014   Phase 3   EUCTR2013-003877-87-HU   Canada;Czech Republic;Hungary;Poland;Slovakia;United States
      2014   Phase 1;Phase 3   EUCTR2013-003877-87-CZ   Canada;Czech Republic;Hungary;Poland;Slovakia;United States
Omalizumab
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 1   NCT00260702   United States
Orencia
   ISTITUTO PER L`INFANZIA BURLO GAROFOLO
      2008   -   EUCTR2008-003368-21-IT   Italy
Orencia® 125 MG solution FOR injection IN PRE-filled syringe
   Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
      2016   Phase 2   EUCTR2015-002491-24-DE   Germany
Orladeyo
   BIOCRYST PHARMACEUTICALS INC.
      2023   Phase 3   EUCTR2021-005932-50-IT   Austria;Canada;France;Germany;Hungary;Israel;Italy;North Macedonia;Poland;Romania;Spain;United Kingdom
   BioCryst Pharmaceuticals Inc
      2021   Phase 3   EUCTR2020-004230-37-SK   Czech Republic;European Union;France;Korea, Republic of;North Macedonia;Poland;Slovakia;South Africa
   BioCryst Pharmaceuticals, Inc.
      2023   Phase 3   EUCTR2021-005932-50-PL   Austria;Canada;France;Germany;Israel;Italy;Poland;Romania;Spain;United Kingdom
      2022   Phase 3   EUCTR2021-005932-50-FR   Austria;Canada;France;Germany;Hungary;Israel;Italy;North Macedonia;Poland;Romania;Spain;United Kingdom
      2022   Phase 3   EUCTR2021-005932-50-DE   Austria;Canada;France;Germany;Israel;Italy;Poland;Romania;Spain;United Kingdom
      2022   Phase 3   EUCTR2021-005932-50-AT   Austria;Canada;France;Germany;Israel;Italy;Poland;Romania;Spain;United Kingdom
Other hematological agents
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
OTL-101
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2018   Phase 1/Phase 2   NCT03765632   United Kingdom
   Great Ormond Street Hospital for Children NHS Trust
      2017   Phase 2   EUCTR2017-001275-23-GB   United Kingdom
OTL-103
   Fondazione Telethon
      2019   Phase 3   NCT03837483   Italy;United States
      2010   Phase 1/Phase 2   NCT01515462   Italy
OTL-103 dispersion FOR infusion
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
Ovastat 1000
   medac Gesellschaft fuer klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-AT   Austria;Czech Republic;Germany;Italy;Poland
   medac Gesellschaft für klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-DE   Austria;Czech Republic;Germany;Italy;Poland
   medac GmbH
      2015   Phase 2   EUCTR2013-005508-33-IT   Austria;Czech Republic;Germany;Italy;Poland
      2014   Phase 2   EUCTR2013-005508-33-PL   Austria;Czech Republic;Germany;Italy;Poland
Ovastat 1000 MG, powder FOR solution FOR infusion
   medac Gesellschaft für klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-CZ   Austria;Czech Republic;Germany;Italy;Poland
Ovastat 5000
   medac Gesellschaft fuer klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-AT   Austria;Czech Republic;Germany;Italy;Poland
   medac Gesellschaft für klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-DE   Austria;Czech Republic;Germany;Italy;Poland
   medac GmbH
      2015   Phase 2   EUCTR2013-005508-33-IT   Austria;Czech Republic;Germany;Italy;Poland
      2014   Phase 2   EUCTR2013-005508-33-PL   Austria;Czech Republic;Germany;Italy;Poland
Ovastat 5000 MG, powder FOR solution FOR infusion
   medac Gesellschaft für klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-CZ   Austria;Czech Republic;Germany;Italy;Poland
Palifermin
   National Institute of Allergy and Infectious Diseases (NIAID)
      2025   Phase 1/Phase 2   NCT06851767   United States
      2024   Phase 1/Phase 2   NCT06325709   United States
      2012   Phase 1/Phase 2   NCT03315078   United States
      2012   Phase 1/Phase 2   NCT01306019   United States
Palliative care
   University of Pittsburgh
      2012   -   NCT03333200   United States
Pantoprazole
   Ospedale San Raffaele
      2015   Phase 2   EUCTR2015-002356-27-IT   Italy
Pantoprazolo 20 MG gastro-resistant tablets
   Ospedale San Raffaele
      2015   Phase 2   EUCTR2015-002356-27-IT   Italy
Pcclchimgp91S lentiviral vector transduced CD34+ cells infusion
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2011   Phase 1/Phase 2   NCT01381003   United Kingdom
PEG-ADA
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2018   Phase 1/Phase 2   NCT03765632   United Kingdom
      2012   Phase 1/Phase 2   NCT01380990   United Kingdom
PEG-interleukin-2
   Mount Sinai School of Medicine
      1997   -   NCT00004695   -
Peripheral blood stem cell transplantation
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2012   Phase 2   NCT01529827   United States
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States
      2000   Phase 1/Phase 2   NCT00305708   United States
Peripheral blood stem cells
   National Institute of Allergy and Infectious Diseases (NIAID)
      2015   Phase 1/Phase 2   NCT02629120   United States
      2014   Phase 1/Phase 2   NCT02282904   United States
PHA-022121
   Academisch Medisch Centrum
      2021   Phase 2   EUCTR2021-000720-36-NL   Netherlands
   Pharvaris Netherlands B.V.
      2023   Phase 2;Phase 3   EUCTR2021-006906-58-IT   Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003445-11-IT   Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
   Pharvaris Netherlands BV
      2023   Phase 2   EUCTR2021-000227-13-IE   Austria;Bulgaria;Canada;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2021-000227-13-AT   Austria;Bulgaria;Canada;Germany;Ireland;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-006906-58-PL   Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-006906-58-HU   Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-006906-58-FR   Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000227-13-PL   Austria;Bulgaria;Canada;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000227-13-BG   Austria;Bulgaria;Canada;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003445-11-PL   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003445-11-NL   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003445-11-HU   Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
      2021   Phase 2   EUCTR2020-003445-11-ES   Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
      2021   Phase 2   EUCTR2020-003445-11-DE   Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
      2021   Phase 2   EUCTR2020-003445-11-BG   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-003445-11-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
      -   Phase 2   EUCTR2020-003445-11-CZ   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
PHA-022121 monohydrate
   Academisch Medisch Centrum
      2023   Phase 2   EUCTR2022-003168-25-NL   Netherlands
Phagocyte oxidase subunit transduced CD34 hematopoietic stem cells
   National Institute of Allergy and Infectious Diseases (NIAID)
      2006   Early Phase 1   NCT00394316   United States
Pheripheral blood stem cells
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT05463133   United States
Phosphate
   Shire
      2005   Phase 3   NCT00262080   United States
Phosphate buffer saline (PBS), PH 7.0
   Shire
      2007   Phase 3   NCT00457015   Canada;Jordan;United States
PHVS416
   Pharvaris Netherlands B.V.
      2023   Phase 2;Phase 3   EUCTR2021-006906-58-IT   Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003445-11-IT   Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
   Pharvaris Netherlands BV
      2023   Phase 2   EUCTR2021-000227-13-IE   Austria;Bulgaria;Canada;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2021-000227-13-AT   Austria;Bulgaria;Canada;Germany;Ireland;Israel;Italy;Poland;Spain;Switzerland;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-006906-58-PL   Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-006906-58-HU   Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-006906-58-FR   Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000227-13-PL   Austria;Bulgaria;Canada;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000227-13-BG   Austria;Bulgaria;Canada;Germany;Ireland;Israel;Italy;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003445-11-PL   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003445-11-NL   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003445-11-HU   Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
      2021   Phase 2   EUCTR2020-003445-11-ES   Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
      2021   Phase 2   EUCTR2020-003445-11-DE   Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
      2021   Phase 2   EUCTR2020-003445-11-BG   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2020-003445-11-FR   Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom
      -   Phase 2   EUCTR2020-003445-11-CZ   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;United States
PID
   Children's Hospital of Chongqing Medical University
      2020   Phase 0   ChiCTR2000032139   China
Pioglitazone
   Children's Hospital of Fudan University
      2017   Phase 1/Phase 2   NCT03080480   China
   NHS Tayside
      2016   Phase 4   NCT02733679   United Kingdom
Plerixafor
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2019   Phase 2   NCT03547830   Russian Federation
      2016   Phase 2   NCT03019809   Russian Federation
   Fondazione Telethon
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy
   National Institute of Allergy and Infectious Diseases (NIAID)
      2025   Phase 1/Phase 2   NCT06851767   United States
      2024   Phase 1/Phase 2   NCT06325709   United States
      2014   Phase 2/Phase 3   NCT02231879   United States
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
   Ospedale San Raffaele
      2015   Phase 2   EUCTR2015-002356-27-IT   Italy
PM359
   Prime Medicine, Inc.
      2024   Phase 1/Phase 2   NCT06559176   Canada;United Kingdom;United States
Pncj PPS
   Institut National de la Santé Et de la Recherche Médicale, France
      2009   Phase 2   NCT01489618   France
Pneumo 23
   Inserm
      2009   Phase 2   EUCTR2007-003235-23-FR   France
Polyclonal IGG
   Federico II University
      2010   -   NCT03534479   Italy
Polymerase chain reaction
   University Hospital Freiburg
      2007   -   NCT00499070   Austria;Belgium;Czech Republic;Denmark;Germany;Ireland;Italy;Netherlands;Poland;Spain;Switzerland
Posaconazole
   Radboud University
      2009   Phase 2   NCT00799071   Netherlands;United Kingdom
   Radboud University Nijmegen Medical Centre
      2009   -   EUCTR2008-004518-28-GB   Netherlands;United Kingdom
Prednisone
   Fairview University Medical Center
      2000   -   NCT00006054   United States
Prevenar
   Great Ormond Street Hospital
      2005   Phase 4   EUCTR2005-004122-70-GB   United Kingdom
   Inserm
      2009   Phase 2   EUCTR2007-003235-23-FR   France
   Institute of Child Health
      2006   Phase 3   NCT00656409   United Kingdom
   Sheba Medical Center
      2010   -   NCT01075438   Israel
Privigen
   CSL Behring AG
      -   -   EUCTR2014-003772-23-Outside-EU/EEA   United States
   CSL Behring KK
      -   Phase 3   EUCTR2016-001631-12-Outside-EU/EEA   Japan
Progynova 21 mite
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany
Proleukin® S
   Universitätsklinikum Freiburg
      2016   Phase 2   EUCTR2015-003369-27-DE   Germany
Promacta
   Weill Medical College of Cornell University
      2009   Phase 2   NCT00909363   United States
PSRS11.EFS.IL2RG.PRE* retroviral vector
   Great Ormond Street Hospital NHS Trust / University College London - Institute of Child Health
      2010   Phase 1;Phase 2   EUCTR2007-000684-16-GB   United Kingdom
PTH 1-34
   National Institute of Dental and Craniofacial Research (NIDCR)
      2006   Phase 3   NCT00395538   Austria;Italy;United States
Pyrimethamine
   National Institute of Allergy and Infectious Diseases (NIAID)
      2003   Phase 1   NCT00065390   United States
      2001   Phase 1   NCT00013689   United States
Quality-OF-life assessment
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
R-HIL-18BP
   AB2 Bio Ltd.
      2019   Phase 3   EUCTR2018-003297-27-DE   Canada;Germany;United States
      -   Phase 3   EUCTR2018-003199-10-DE   Canada;Germany;United States
Rabbit ANTI-thymocyte globulin
   Enzyvant Therapeutics GmBH
      2005   Phase 1/Phase 2   NCT00579527   United States
   Sumitomo Pharma Switzerland GmbH
      2010   -   NCT01220531   United States
Radiation therapy
   University of California, San Francisco
      2000   Phase 1/Phase 2   NCT00305708   United States
Ranitidine
   National Institute of Allergy and Infectious Diseases (NIAID)
      2007   Phase 2   NCT00527878   United States
Recombinant human C1 esterase inhibitor
   Shire
      2016   Phase 1   NCT02663687   United States
Recombinant human C1 inhibitor
   Laboratorios Dr. Esteve, S.A.
      2005   Phase 3   EUCTR2005-000206-31-ES   Italy;Spain;United Kingdom
   PHARMING TECHNOLOGIES B.V.
      2005   -   EUCTR2004-004282-15-IT   Italy
      2004   -   EUCTR2005-000206-31-IT   Italy;Spain;United Kingdom
   Pharming Technologies B.V.
      2014   Phase 2   NCT02247739   Canada;Czech Republic;Czechia;Italy;Macedonia, The Former Yugoslav Republic of;Netherlands;Romania;Serbia;United States
      2011   -   EUCTR2011-000049-19-HU   Hungary;Italy
      2009   Phase 2   NCT00851409   Netherlands;Romania
      2005   Phase 2/Phase 3   NCT00225147   Netherlands;United States
      2004   Phase 3   NCT00262301   Netherlands;Romania
      -   Phase 3   EUCTR2005-000206-31-GB   Italy;Spain;United Kingdom
Recombinant human hyaluronidase
   Baxalta now part of Shire
      2011   Phase 2/Phase 3   NCT01485796   United States
      2008   Phase 3   NCT00814320   Canada;United States
   Baxter Innovations GmbH
      2012   -   EUCTR2012-000481-38-GB   Belgium;Czech Republic;Germany;Italy;Netherlands;Sweden;Switzerland;United Kingdom
   Nishizawa Atsushi
      2022   Phase 3   JPRN-jRCT2041220059   -
      2022   Phase 3   JPRN-jRCT2031210457   -
Recombinant human hyaluronidase + immune globulin intravenous
   Baxalta now part of Shire
      2006   Phase 1/Phase 2   NCT00782106   United States
Reduced intensity conditioning
   National Cancer Institute (NCI)
      2018   Phase 2   NCT03663933   United States
      2015   Phase 2   NCT02579967   United States
Reduced intensity preparative regimen
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States
Reduced toxicity ablative regimen
   Masonic Cancer Center, University of Minnesota
      2014   -   NCT02179359   United States
Retroviral SF71-GP91phox transduced CD34+ cells
   Johann Wolfgang Goethe University Hospitals
      2004   Phase 1/Phase 2   NCT00564759   Germany
   University of Zurich
      2004   Phase 1/Phase 2   NCT00927134   Switzerland
Retrovirus-mediated gene transfer
   David Williams
      2011   Phase 1/Phase 2   NCT01410825   United States
RHC1IHN
   Pharming Technologies B.V.
      -   Phase 3   EUCTR2005-000206-31-GB   Italy;Spain;United Kingdom
RHC1INH
   Laboratorios Dr. Esteve, S.A.
      2005   Phase 3   EUCTR2005-000206-31-ES   Italy;Spain;United Kingdom
   PHARMING GROUP NV
      2015   Phase 2   EUCTR2014-002839-33-IT   Canada;Czech Republic;Czechia;Israel;Italy;North Macedonia;Poland;Romania;Serbia;United States
   PHARMING TECHNOLOGIES B.V.
      2011   Phase 2   EUCTR2011-000987-92-IT   Czech Republic;Germany;Hungary;Israel;Italy;Slovakia
      2011   Phase 3   EUCTR2011-000049-19-IT   Argentina;Hungary;Italy;Macedonia, the former Yugoslav Republic of;South Africa;United States
      2005   -   EUCTR2004-004282-15-IT   Italy
      2004   -   EUCTR2005-000206-31-IT   Italy;Spain;United Kingdom
   Pharming Group NV
      2015   Phase 2   EUCTR2014-002839-33-CZ   Canada;Czech Republic;Israel;Italy;Macedonia, the former Yugoslav Republic of;Poland;Romania;Serbia;United States
   Pharming Technologies B.V.
      2018   -   NCT03697187   United States
      2012   Phase 2   NCT01359969   Czech Republic;Czechia;Germany;Hungary;Israel;Italy;Macedonia, The Former Yugoslav Republic of;North Macedonia;Poland;Romania;Slovakia;United States
      2011   Phase 3   NCT01188564   Bulgaria;Canada;Hungary;Israel;Italy;Macedonia, The Former Yugoslav Republic of;Netherlands;Poland;Romania;Serbia;South Africa;United States
      2011   -   EUCTR2011-000049-19-HU   Hungary;Italy
RHC1INH or PDC1INH
   Pharming Technologies B.V.
      2011   -   NCT01397864   Bulgaria;Croatia;Czech Republic;Czechia;France;Germany;Hungary;Italy;Macedonia, The Former Yugoslav Republic of;Netherlands;North Macedonia;Norway;Poland;Slovakia;Slovenia;Sweden
Rhucd40L
   National Institute of Allergy and Infectious Diseases (NIAID)
      1999   Phase 2   NCT00001145   United States
RI-002
   ADMA Biologics, Inc.
      2014   Phase 3   NCT01814800   United States
Rifaximin
   Oslo University Hospital
      2013   Phase 4   NCT01946906   Norway
Rimiducid
   Bellicum Pharmaceuticals
      2017   Phase 1/Phase 2   NCT03733249   Italy;Saudi Arabia;United Kingdom
      2014   Phase 1/Phase 2   NCT02065869   Germany;Italy;Spain;United Kingdom;United States
Rituximab
   Fondazione Telethon
      2010   Phase 1;Phase 2   EUCTR2009-017346-32-IT   Italy
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
   Medical College of Wisconsin
      2016   Phase 2   NCT02789397   -
   National Center for Child Heath and Development
      2018   Phase 1,2   JPRN-UMIN000030806   Japan
   Orchard Therapeutics Ltd.
      2019   Phase 3   EUCTR2018-003842-18-IT   Italy
Rivogenlecleucel
   Bellicum Pharmaceuticals
      2017   Phase 1/Phase 2   NCT03733249   Italy;Saudi Arabia;United Kingdom
Romiplostim
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2019   Phase 2   NCT04371939   Russian Federation
      2012   -   NCT04350164   Russian Federation
Rosuvastatin + BCX7353
   BioCryst Pharmaceuticals
      2017   Phase 1   NCT03136237   United Kingdom
RP-L201
   Rocket Pharmaceuticals Inc.
      2019   Phase 1   NCT03825783   Spain
      2019   Phase 1/Phase 2   NCT03812263   Spain;United Kingdom;United States
   Rocket Pharmaceuticals, Inc.
      2020   Phase 1;Phase 2   EUCTR2020-000517-33-GB   Spain;United Kingdom;United States
      2018   Phase 1   EUCTR2018-002680-26-ES   Spain
RTX
   Medical College of Wisconsin
      2016   Phase 2   NCT02789397   -
Ruconest
   Bernstein Clinical Research Center
      2018   Phase 4   NCT06690047   United States
   PHARMING TECHNOLOGIES B.V.
      2011   Phase 2   EUCTR2011-000987-92-IT   Czech Republic;Germany;Hungary;Israel;Italy;Slovakia
      2011   Phase 3   EUCTR2011-000049-19-IT   Argentina;Hungary;Italy;Macedonia, the former Yugoslav Republic of;South Africa;United States
   Pharming Group NV
      2015   Phase 2   EUCTR2014-002839-33-CZ   Canada;Czech Republic;Israel;Italy;Macedonia, the former Yugoslav Republic of;Poland;Romania;Serbia;United States
   Pharming Technologies B.V.
      2015   Phase 2   EUCTR2011-000987-92-HU   Czech Republic;Germany;Hungary;Israel;Italy;Macedonia, the former Yugoslav Republic of;Slovakia
      2014   Phase 2   EUCTR2011-000987-92-SK   Czech Republic;Germany;Hungary;Israel;Italy;Slovakia
      2014   Phase 2   EUCTR2011-000987-92-CZ   Czech Republic;Germany;Hungary;Israel;Italy;Slovakia
      2011   Phase 2   EUCTR2011-000987-92-DE   Czech Republic;Germany;Hungary;Israel;Italy;Macedonia, the former Yugoslav Republic of;Poland;Romania;Slovakia
Ruconest - 2100 U - polvere PER soluzione iniettabile - USO endovenoso - flaconcino(vetro) 1 flaconcino DA 2100 U
   PHARMING GROUP NV
      2015   Phase 2   EUCTR2014-002839-33-IT   Canada;Czech Republic;Czechia;Israel;Italy;North Macedonia;Poland;Romania;Serbia;United States
Ruconest 2100 U powder FOR solution FOR injection
   Pharming Technologies B.V.
      2011   -   EUCTR2011-000049-19-HU   Hungary;Italy
Ruxolitinib
   National Institute of Allergy and Infectious Diseases (NIAID)
      2023   Phase 2   NCT05398809   United States
SC investigational needle sets
   Takeda
      2024   Phase 3   NCT06076642   United States
      2023   -   NCT06955793   -
Sebetralstat
   KalVista Pharmaceuticals Ltd
      2023   Phase 3   EUCTR2021-001226-21-SK   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-001226-21-PT   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-001176-42-SK   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-001176-42-PT   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2021-001176-42-IT   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001226-21-NL   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001226-21-GR   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001226-21-DE   Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Slovakia;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-RO   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-PL   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-NL   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-GR   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-FR   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-BG   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-001176-42-AT   Australia;Austria;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;North Macedonia;Poland;Portugal;Romania;Saudi Arabia;Slovakia;South Africa;Spain;United Kingdom;United States
   KalVista Pharmaceuticals, Ltd.
      2025   -   NCT06628713   United States
SHP616
   Shire ViroPharma, Inc.
      2016   Phase 3   EUCTR2015-002478-19-HU   Canada;Germany;Hungary;Israel;Romania;Spain;United States
      2016   Phase 3   EUCTR2015-002478-19-ES   Canada;Germany;Hungary;Israel;Romania;Spain;United States
      2016   Phase 3   EUCTR2015-002478-19-DE   Canada;Germany;Hungary;Israel;Romania;Spain;United States
SHP623
   Shire
      2016   Phase 1   NCT02663687   United States
SHP643
   Shire (Shire is now part of Takeda)
      2020   Phase 3   EUCTR2018-002093-42-DE   Canada;Germany;Hungary;Spain;United States
      2019   Phase 3   EUCTR2018-002093-42-HU   Canada;Germany;Hungary;Spain;United States
      2019   Phase 3   EUCTR2018-002093-42-ES   Canada;Germany;Hungary;Spain;United States
Single infusion OF autologous CD34+ cells transduced with THE SELF-inactivating (SIN) gammaretroviral vector PSRS11.EFS.IL2RG.PRE
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2011   -   NCT01175239   United Kingdom
Sirolimus
   Children's Hospital of Philadelphia
      2006   Phase 1/Phase 2   NCT00392951   United States
   Endo Akifumi
      2022   Phase 2   JPRN-jRCT2031210309   -
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
   Imai Kohsuke
      2023   -   JPRN-jRCTs031230296   -
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT05463133   United States
      2019   Early Phase 1   NCT03910452   United States
      2015   Phase 1/Phase 2   NCT02629120   United States
      2014   Phase 1/Phase 2   NCT02282904   United States
Somatic GENE-therapy BY X-CGD
   Johann Wolfgang Goethe-University
      2013   Phase 1;Phase 2   EUCTR2012-001725-26-DE   Germany
Somatotropin
   Goethe-Universität Frankfurt/Main
      2009   -   EUCTR2009-015739-34-DE   Germany
Somatropin, clonidine, L-arginin-hydrochloride, estradiol valerate
   Johann Wolfgang Goethe University Hospitals
      2010   Phase 4   NCT01052623   Germany
Soquelitinib
   National Institute of Allergy and Infectious Diseases (NIAID)
      2025   Phase 2   NCT06730126   United States
STA-5326
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 1   NCT00263237   United States
STAR-0215
   Astria Therapeutics, Inc.
      2023   Phase 2   NCT06007677   Bulgaria;Canada;Czechia;Germany;United Kingdom;United States
      2023   Phase 1/Phase 2   NCT05695248   Bulgaria;Canada;Czechia;Germany;United Kingdom;United States
      2022   Phase 1   NCT05477160   United States
Stem cell infusion
   Baylor College of Medicine
      2007   Phase 1/Phase 2   NCT00579137   United States
      2004   Phase 2   NCT00578643   United States
      2000   Phase 2   NCT00368355   United States
   Masonic Cancer Center, University of Minnesota
      2002   Phase 2/Phase 3   NCT00176852   United States
Stem cell transplant
   Masonic Cancer Center, University of Minnesota
      2015   -   NCT02162420   United States
      2000   Phase 2/Phase 3   NCT00176878   United States
Stem cell transplantation
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2012   Phase 1/Phase 2   NCT01380990   United Kingdom
   Masonic Cancer Center, University of Minnesota
      2012   -   NCT01652092   United States
      2007   Phase 2/Phase 3   NCT00455312   United States
   National Center for Child Health and Development
      2017   -   JPRN-UMIN000030647   Japan
      2016   -   JPRN-UMIN000022688   Japan
   Sakaguchi Hirotoshi
      2018   Phase 2   JPRN-jRCTs031180398   Japan;None (Japan only)
Strimvelis
   Orchard Therapeutics (Europe) Ltd
      2017   Phase 4   EUCTR2017-001731-39-IT   Italy;Switzerland;Turkey
Subcuvia
   Baxter Innovations GmbH
      2012   Phase 2;Phase 3   EUCTR2010-019459-23-BE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2011   -   EUCTR2010-019459-23-SE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2011   Phase 2;Phase 3   EUCTR2010-019459-23-NL   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2011   -   EUCTR2010-019459-23-DE   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2010-019459-23-HU   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2010-019459-23-GB   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
      2010   -   EUCTR2010-019459-23-AT   Austria;Belgium;Germany;Hungary;Netherlands;Sweden;United Kingdom
Subgam
   Bio Products Laboratory
      2015   Phase 3   NCT01884311   United States
Sulfadoxine
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00013689   United States
Suspension OF autologous CD34+cells transduced with THE G1xcgd viral vector
   GENETHON
      2013   Phase 1;Phase 2   EUCTR2012-000242-35-DE   France;Germany;Switzerland;United Kingdom
   Genethon
      2013   Phase 1;Phase 2   EUCTR2012-000242-35-GB   France;Germany;Switzerland;United Kingdom
T-cell depleted & CD34+select/W/stemcell enriched product
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 3   NCT00023192   United States
Tabelecleucel
   Atara Biotherapeutics
      2021   Phase 2   NCT04554914   Austria;Belgium;France;Italy;Spain;United Kingdom;United States
      2016   -   NCT02822495   United States
Tacrolimus
   Boston Children's Hospital
      2012   Phase 2   NCT01659606   Norway;Sweden;United States
   Enzyvant Therapeutics GmBH
      2005   Phase 1/Phase 2   NCT00579527   United States
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States
   Roswell Park Cancer Institute
      2012   Phase 2   NCT01529827   United States
   Sumitomo Pharma Switzerland GmbH
      2010   -   NCT01220531   United States
Tadekinig alfa
   AB2 Bio Ltd.
      2019   Phase 3   EUCTR2018-003297-27-DE   Canada;Germany;United States
      2018   Phase 3   NCT03512314   Canada;Germany;United States
      2017   Phase 3   NCT03113760   Canada;Germany;United States
      -   Phase 3   EUCTR2018-003199-10-DE   Canada;Germany;United States
TAK-667
   Takeda
      2021   Phase 3   NCT04654351   Japan
   Takeda Pharmaceutical Company Limited
      -   Phase 3   EUCTR2022-002627-35-Outside-EU/EEA   Japan
TAK-743, SHP643, DX-2930
   Takeda
      -   Phase 3   EUCTR2023-001105-31-Outside-EU/EEA   China
TAK-771
   Nishizawa Atsushi
      2022   Phase 3   JPRN-jRCT2041220059   -
      2022   Phase 3   JPRN-jRCT2031210457   -
   Takeda
      2022   Phase 3   NCT05513586   Japan
      2022   Phase 3   NCT05150340   Japan
TAK-881
   Takeda
      2024   Phase 3   NCT06076642   United States
      2023   -   NCT06955793   -
      2023   Phase 2/Phase 3   NCT05755035   Czechia;Denmark;Germany;Netherlands;Poland;Slovakia;Spain;United States
TAK743
   Shire (Shire is now part of Takeda)
      2020   Phase 3   EUCTR2018-002093-42-DE   Canada;Germany;Hungary;Spain;United States
      2019   Phase 3   EUCTR2018-002093-42-HU   Canada;Germany;Hungary;Spain;United States
      2019   Phase 3   EUCTR2018-002093-42-ES   Canada;Germany;Hungary;Spain;United States
   Takeda
      -   Phase 3   EUCTR2023-001105-31-Outside-EU/EEA   China
Takhzyro
   Shire (Shire is now part of Takeda)
      2020   Phase 3   EUCTR2018-002093-42-DE   Canada;Germany;Hungary;Spain;United States
      2019   Phase 3   EUCTR2018-002093-42-HU   Canada;Germany;Hungary;Spain;United States
      2019   Phase 3   EUCTR2018-002093-42-ES   Canada;Germany;Hungary;Spain;United States
   Takeda
      -   Phase 3   EUCTR2023-001105-31-Outside-EU/EEA   China
TBI
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
TCR alfa beta T cell depletion
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2012   Phase 2/Phase 3   NCT02327351   Russian Federation
Temozolomide
   National Cancer Institute (NCI)
      2023   Phase 1/Phase 2   NCT05691491   United States
Thalidomide
   Kawai Toshinao
      2017   Phase 2-3   JPRN-jRCT2031200236   -
   National Center for Child Heath and Development
      2017   -   JPRN-UMIN000029324   Japan
      2012   -   JPRN-UMIN000009370   Japan
Therapeutic allogeneic lymphocytes
   University of California, San Francisco
      2005   Phase 1   NCT00295971   United States
There IS NO recommended INN
   Great Ormond Street Hospital for Children NHS Trust
      2017   Phase 2   EUCTR2017-001275-23-GB   United Kingdom
Thiotepa
   Paul Szabolcs
      2014   Phase 2   NCT01962415   United States
   University of California, San Francisco
      2005   Phase 1   NCT00295971   United States
Thiotepa--escalated dose
   University of Florida
      2018   Phase 1/Phase 2   NCT03513328   United States
Thiotepa--single daily dose
   University of Florida
      2018   Phase 1/Phase 2   NCT03513328   United States
Thymafalsin
   Erasmus MC
      2022   Phase 2   EUCTR2021-003327-15-NL   Netherlands
Thymalfasin
   Erasmus MC
      2022   Phase 2   EUCTR2021-003327-15-NL   Netherlands
Thymus tissue FOR transplantation
   M. Louise Markert
      2002   Phase 1   NCT00579709   United States
Thymus/parathyroid transplantation
   M. Louise Markert
      2005   Phase 1   NCT00566488   United States
TO BE confirmed
   Kalvista Pharmaceuticals Ltd
      2021   Phase 2   EUCTR2021-000136-59-HU   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000136-59-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000136-59-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000136-59-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;New Zealand;North Macedonia;Romania;United Kingdom;United States
Tociluzumab
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT05463133   United States
Tofacitinib
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT05104723   United States
Total body 200CGY
   National Institute of Allergy and Infectious Diseases (NIAID)
      2014   Phase 1/Phase 2   NCT02282904   United States
Total body irradiation
   Baylor College of Medicine
      2000   Phase 2   NCT00368355   United States
   Masonic Cancer Center, University of Minnesota
      2018   Phase 2   NCT03579875   United States
      2015   -   NCT02162420   United States
      2007   Phase 2/Phase 3   NCT00455312   United States
      2002   Phase 2/Phase 3   NCT00176852   United States
   National Cancer Institute (NCI)
      2020   Phase 2   NCT04339777   United States
   National Center for Child Health and Development
      2017   -   JPRN-UMIN000030647   Japan
      2016   -   JPRN-UMIN000022688   Japan
   National Institute of Allergy and Infectious Diseases (NIAID)
      2022   Phase 1/Phase 2   NCT05463133   United States
      2019   Early Phase 1   NCT03910452   United States
      2015   Phase 1/Phase 2   NCT02629120   United States
   Sakaguchi Hirotoshi
      2018   Phase 2   JPRN-jRCTs031180398   Japan;None (Japan only)
Total lymphoid irradiation
   Masonic Cancer Center, University of Minnesota
      2000   Phase 2/Phase 3   NCT00176878   United States
Total-body irradiation
   Fred Hutchinson Cancer Research Center
      2006   Phase 2   NCT00358657   United States
      1997   Phase 1   NCT00008450   United States
   Roswell Park Cancer Institute
      2017   Phase 2   NCT03333486   United States
      2012   Phase 2   NCT01529827   United States
   University of California, San Francisco
      2005   Phase 1   NCT00295971   United States
Traditional treatment OF CGD and TB
   Children's Hospital of Fudan University
      2019   Phase 2/Phase 3   NCT03984890   China
Tranexamic acid
   JERINI AG
      2005   -   EUCTR2004-001540-71-IT   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
   Jerini AG
      2005   -   EUCTR2004-001540-71-SE   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-LT   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-001540-71-IE   Austria;Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-HU   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   Phase 3   EUCTR2004-001540-71-GB   Austria;Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-DE   Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-001540-71-AT   Austria;Germany;Hungary;Ireland;Italy;Lithuania;Sweden;United Kingdom
   Shire
      2005   Phase 3   NCT00500656   Italy
Transplant preparative regimen OF alemtuzumab, fludarabine, thiotepa, and melphalan
   Washington University School of Medicine
      2013   Phase 2   NCT01821781   United States
Treosulfan
   Federal Research Institute of Pediatric Hematology, Oncology and Immunology
      2020   Phase 2   NCT04400045   Russian Federation
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
   GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST
      2014   Phase 4   EUCTR2013-003257-20-GB   United Kingdom
   medac Gesellschaft fuer klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-AT   Austria;Czech Republic;Germany;Italy;Poland
   medac Gesellschaft für klinische Spezialpräparate mbH
      2014   Phase 2   EUCTR2013-005508-33-DE   Austria;Czech Republic;Germany;Italy;Poland
      2014   Phase 2   EUCTR2013-005508-33-CZ   Austria;Czech Republic;Germany;Italy;Poland
   medac GmbH
      2015   Phase 2   NCT02349906   Austria;Czech Republic;Czechia;Germany;Italy;Poland
      2015   Phase 2   EUCTR2013-005508-33-IT   Austria;Czech Republic;Germany;Italy;Poland
      2014   Phase 2   EUCTR2013-005508-33-PL   Austria;Czech Republic;Germany;Italy;Poland
Triheptanoin
   The University of Queensland
      2022   Phase 2   NCT04513002   Australia
Tuvusertib
   National Cancer Institute (NCI)
      2023   Phase 1/Phase 2   NCT05691491   United States
Umbilical cord blood transplantation
   University of California, San Francisco
      2005   Phase 2   NCT00301834   United States
      2000   Phase 1/Phase 2   NCT00305708   United States
Ustekinumab
   National Institute of Allergy and Infectious Diseases (NIAID)
      2018   Phase 1/Phase 2   NCT03366142   United States
      2015   Phase 1/Phase 2   NCT02199496   United States
Valproic acid
   Koneti Rao
      2008   Phase 1/Phase 2   NCT00605657   United States
Verorab® (pvrv
   Chulalongkorn University
      2015   Phase 4   NCT02490956   Thailand
Vigantol
   Karolinska University Hospital
      2010   Phase 1/Phase 2   NCT01131858   Sweden
Vinblastine, vincristine, prednisone, daunorubicin
   St. Jude Children's Research Hospital
      2002   -   NCT00187057   United States
Vitamin D3
   Children's Hospital of Fudan University
      2019   Phase 2/Phase 3   NCT03984890   China
Vivaglobin
   CSL Behring
      2007   Phase 4   NCT00520494   Belgium;Canada;Germany;Italy;Spain
   CSL Behring AG
      2008   Phase 4   EUCTR2006-006522-25-GR   Belgium;Germany;Greece;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006522-25-IT   Belgium;Germany;Greece;Italy;Spain;United Kingdom
      2007   Phase 4   EUCTR2006-006522-25-GB   Belgium;Germany;Greece;Italy;Spain;United Kingdom
      2007   Phase 4   EUCTR2006-006522-25-ES   Belgium;Germany;Greece;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006522-25-DE   Belgium;Germany;Greece;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006522-25-BE   Belgium;Germany;Greece;Italy;Spain;United Kingdom
VM106
   Helixmith Co., Ltd.
      2007   Phase 1/Phase 2   NCT00778882   Korea, Republic of
VP 20624
   Shire ViroPharma Incorporated
      2014   Phase 3   EUCTR2013-002453-29-GB   Germany;Italy;Mexico;Romania;United Kingdom;United States
      2014   Phase 3   EUCTR2013-002453-29-DE   Germany;Mexico;Romania;United Kingdom;United States
   ViroPharma Incorporated
      2014   Phase 3   EUCTR2013-002453-29-RO   Argentina;Germany;Italy;Mexico;Romania;Spain;United Kingdom;United States
      2012   -   EUCTR2011-000369-11-DE   Germany;Hungary;United States
      2011   -   EUCTR2011-000369-11-HU   Germany;Hungary;United States
      -   Phase 3   EUCTR2013-002453-29-IT   Argentina;Germany;Italy;Mexico;Romania;Spain;United Kingdom;United States
Whole exome sequencing
   University Hospital, Strasbourg, France
      2018   -   NCT03427593   France
X vivo gene therapy
   Genethon
      2016   Phase 1/Phase 2   NCT02757911   France
      2013   Phase 1/Phase 2   NCT01855685   Germany;Switzerland;United Kingdom
X-RAY imaging
   Fred Hutchinson Cancer Center
      2022   Phase 2   NCT04965597   United States
X4P-001
   X4 PHARMACEUTICALS, INC.
      2020   Phase 3   EUCTR2019-001153-10-IT   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
   X4 Pharmaceuticals
      2016   Phase 2   NCT03005327   Australia;United States
   X4 Pharmaceuticals Incorporated
      2020   Phase 3   EUCTR2019-001153-10-PL   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-NL   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-HU   Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-GB   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-FR   Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-ES   Australia;Austria;Belgium;Canada;Denmark;European Union;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-DE   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001153-10-AT   Australia;Austria;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
      2019   Phase 3   EUCTR2019-001153-10-DK   Australia;Austria;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
Xifaxan
   Oslo University hospital
      2013   Phase 2   EUCTR2013-000883-27-NO   Norway
Zadaxin
   Erasmus MC
      2022   Phase 2   EUCTR2021-003327-15-NL   Netherlands
Zarzio
   Sandoz GmbH
      2012   Phase 4   EUCTR2011-001118-32-SE   Germany;Sweden
Zoledronate
   Department of Pediatrics, Tokyo Medical and Dental University
      2014   -   JPRN-UMIN000013102   Japan